<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01119950</url>
  </required_header>
  <id_info>
    <org_study_id>CNVA237A2208</org_study_id>
    <secondary_id>2009-014038-11</secondary_id>
    <nct_id>NCT01119950</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, 2-period, Cross-over Study to Assess the Efficacy and Safety of Differing Doses of NVA237 Administered Either Once Daily or Twice Daily, in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study was designed to investigate the efficacy and safety of NVA237, a long-acting
      muscarinic antagonist, in patients with moderate to severe COPD.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximal Response of Incremental Once Daily and Twice Daily Doses of NVA237 That Each Dose Achieves in Relation to the Maximal Effect of NVA237 on Trough Forced Expiratory Volume in One Second at Day 28</measure>
    <time_frame>Day 28</time_frame>
    <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. The maximal response of incremental once daily and twice daily doses of NVA237 that each dose achieves in relation to the maximal effect of NVA237 on Trough FEV1 was measured at Day 28. FEV1 was measured in response to all doses administered (see Outcome Measure #19).
All trough FEV1 responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All trough FEV1 data are reported as a percentage of the theoretical maximal response.
Trough FEV1 was defined as the mean of the 23 hour 15 minute and 23 hour 45 minute post-dose values.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Trough Forced Expiratory Volume in One Second for Once and Twice Daily Regimens of NVA237 for the Same Total Daily Dose of NVA237</measure>
    <time_frame>day 28</time_frame>
    <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer.
FEV1 was measured between dosing regimens (over the range 20 micrograms to 55 micrograms total daily dose) after 28 days of treatment.
Mean trough FEV1 was measured in response to all doses administered (12.5 µg q.d., 25.0 µg q.d., 12.5 µg b.i.d., 50 µg q.d., 25 µg b.i.d., 100 µg q.d., 50.0 µg b.i.d., and Placebo; see Outcome Measure # 19), and was used to compute modeled dose-response curves for once-daily and twice-daily regimens separately. The difference between those curves was computed at pre-specified theoretical doses (20 µg, 25 µg, 30 µg, 35 µg, 40 µg, 45 µg, 50 µg, and 55 µg) chosen at points likely to show the largest differences between the once-daily and twice-daily regimens. The theoretical responses to each dosing schedule separately and the difference between the once-daily and twice-daily regimens are represented below.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of the Maximal Response of NVA237 Doses on Forced Expiratory Volume in One Second Area Under the Curve 0-24 Hours at Day 28 of Treatment</measure>
    <time_frame>5 min, 15 min, 1,2,3,4,6,8,10 hours, 11 hours 55 min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on day 28</time_frame>
    <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer.
Percentage of the maximal response of NVA237 doses on FEV1 Area Under the Curve (AUC) 0-24 hours at day 28 of treatment was calculated from measurements taken at 5 min, 15 min, 1,2,3,4,6,8,10 hours, 11 hours 55 min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on day 28.
AUC FEV1 was measured in response to all doses administered (see Outcome Measure #20). All FEV1 responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All FEV1 data are reported as a percentage of the theoretical maximal response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in One Second AUC 0-24 Hours for Once and Twice Daily Regimens of NVA237 for the Same Total Daily Dose of NVA237, After 28 Days of Treatment</measure>
    <time_frame>-25 min,-15 min (predose); 5 min,15 min, 1,2,3,4,6,8,10 hours, 11 hours 55min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on day 28</time_frame>
    <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer.
The Area Under the Curve (AUC) 0-24 hours FEV1 between dosing regimens over the range 20 micrograms to 55 micrograms total daily dose at -25 min,-15 min (predose); 5 min, 15 min, 1,2,3,4,6,8,10 hours, 11 hours 55 min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on day 28.
AUC 0-24 hours FEV1 was measured in response to all doses administered (12.5 µg q.d., 25.0 µg q.d., 12.5 µg b.i.d., 50 µg q.d., 25 µg b.i.d., 100 µg q.d., 50.0 µg b.i.d., and Placebo; see Outcome Measure # 20), and was used to compute modeled dose-response curves for once-daily and twice-daily regimens separately. The difference between those curves was computed at pre-specified theoretical doses (20 µg, 25 µg, 30 µg, 35 µg, 40 µg, 45 µg, 50 µg, and 55 µg) chosen at points likely to show the largest differences between the once-daily and twice-daily regimens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of the Maximal Response of NVA237 Doses on Forced Expiratory Volume in One Second Area Under the Curve at Different Time Points (0-4 Hours, 0-8 Hours, 0-12 Hours, 12-24 Hours) on Day 28</measure>
    <time_frame>5 min,15 min, 1,2,3,4,6,8,10 hours, 11 hours 55 min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on day 28</time_frame>
    <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer.
Percentage of the maximal response of NVA237 doses on FEV1 Area Under the Curve (AUC) 0-4 Hours, 0-8 Hours, 0-12 Hours, 12-24 Hours were calculated from measurements taken at: 5 min, 15 min, 1,2,3,4,6,8,10 hours, 11 hours 55 min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on day 28.
AUC FEV1 was measured in response to all doses administered (see Outcome Measure #21). All FEV1 responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All FEV1 data are reported as a percentage of the theoretical maximal response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of the Maximal Response of NVA237 Doses on Forced Expiratory Volume in One Second at 12 Hours at Day 28 of Treatment</measure>
    <time_frame>12 hours on day 28</time_frame>
    <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Percentage of the maximal response within different doses/regimens of NVA237 was measured using FEV1 at 12 hours on day 28 of treatment.
FEV1 was measured in response to all doses administered (see Outcome Measure #22). All FEV1 responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All FEV1 data are reported as a percentage of the theoretical maximal response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of the Maximal Response of NVA237 Doses on Peak Forced Expiratory Volume in One Second at Day 28 of Treatment</measure>
    <time_frame>day 28</time_frame>
    <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Peak FEV1 is the maximum FEV1 recorded in a pre-determined period of time.
Percentage of the maximal response of NVA237 within different doses/regimens of NVA237 on Peak FEV1 was measured at day 28 of treatment.
Peak FEV1 was measured in response to all doses administered (see Outcome Measure #23). All FEV1 responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All FEV1 data are reported as a percentage of the theoretical maximal response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of the Maximal Response of NVA237 Doses on Forced Vital Capacity at Day 28 of Treatment</measure>
    <time_frame>day 28</time_frame>
    <description>Percentage of the maximal response of NVA237 within different doses/regimens of NVA237 on Forced Vital Capacity (FVC) was measured at day 28 of treatment. FVC is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible.
FVC at day 28 of treatment was measured via spirometry (see Outcome Measure #24). All FVC responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All FVC data are reported as a percentage of the theoretical maximal response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of the Maximal Response of NVA237 Doses on Trough Forced Expiratory Volume in One Second at Days 1, 7 and 14</measure>
    <time_frame>Days 1, 7 and 14</time_frame>
    <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Percentage of the maximal response of NVA237 doses on Trough FEV1 was measured on Days 1, 7 and 14.
Through FEV1 was measured in response to all doses administered (see Outcome Measure #25). All FEV1 responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All FEV1 data are reported as a percentage of the theoretical maximal response.
Trough FEV1 was defined as the mean of the 23 hour 15 minute and 23 hour 45 minute post-dose values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of the Maximal Effect of NVA237 Doses on Forced Expiratory Volume in One Second Area Under the Curve 0-24 Hours on Days 1 and 14 of Treatment</measure>
    <time_frame>5 min,15 min, 1,2,3,4,6,8,10 hours, 11 hours 55min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on days 1 and 14</time_frame>
    <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer.
Percentage of the maximal response of NVA237 doses on FEV1 Area Under the Curve (AUC) 0-24 hours, was calculated from measurements taken at 5 min,15 min, 1,2,3,4,6,8,10 hours, 11 hours 55min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on days 1 and 14.
FEV1 AUC 0-24 hours was measured on days 1 and 14 of treatment in response to all doses administered (see Outcome Measure #26). All FEV1 responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All FEV1 data are reported as a percentage of the theoretical maximal response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of the Maximal Response of NVA237 Doses on Forced Expiratory Volume in One Second Area Under the Curve 0-4 Hours on Days 1, 7 and 14 of Treatment</measure>
    <time_frame>5 min,15 min, 1,2,3,4 hours (postdose) on Days 1, 7 and 14</time_frame>
    <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer.
Percentage of the maximal response of NVA237 doses on FEV1 Area Under the Curve (AUC) 0-4 hours was calculated from measurements taken at 5 min,15 min, 1,2,3,4 hours (postdose) on Days 1, 7 and 14, in response to all doses administered (see Outcome Measure #27).
All AUC FEV1 responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All FEV1 data are reported as a percentage of the theoretical maximal response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of the Maximal Response of NVA237 Doses on Forced Expiratory Volume in One Second of Area Under the Curve 0-8 Hours Days 1, 7, and 14</measure>
    <time_frame>at 5 min,15 min, 1,2,3,4,6,8 hours (postdose) on days 1, 7 and 14</time_frame>
    <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Percentage of the maximal response of NVA237 doses on FEV1 Area Under the Curve (AUC) 0-8 was calculated from measurements taken at 5 min,15 min, 1,2,3,4,6,8 hours (postdose) on days 1, 7, and 14.
AUC FEV1 was measured in response to all doses administered (see Outcome Measure #28). All FEV1 responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All FEV1 data are reported as a percentage of the theoretical maximal response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of the Maximal Response of NVA237 Doses on Forced Expiratory Volume in One Second Area Under the Curve 0-12 Hours at Day 1 and 14 of Treatment</measure>
    <time_frame>5 min,15 min, 1,2,3,4,6,8,10 hours, 11h 55 min (postdose) on days 1 and 14</time_frame>
    <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Percentage of the maximal response of NVA237 doses was calculated on FEV1 Area Under the Curve (AUC) 0-12 hours from measurements taken at at 5 min,15 min, 1,2,3,4,6,8,10 hours, 11h 55 min (postdose) on days 1 and 14 in response to all doses administered (see Outcome Measure #29).
All AUC FEV1 responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All FEV1 data are reported as a percentage of the theoretical maximal response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of the Maximal Response of NVA237 Doses on Forced Expiratory Volume in One Second of Area Under the Curve 12-24 Hours Over Days 1, and 14 of Treatment</measure>
    <time_frame>11 hours 55 min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on Days 1 and 14</time_frame>
    <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Percentage of the maximal response of NVA237 on FEV1 Area under the curve (AUC) 12-24 hours was calculated from measurements taken at 11 hours 55 min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on Days 1 and 14.
AUC FEV1 was measured in response to all doses administered (see Outcome Measure #30). All FEV1 responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All FEV1 data are reported as a percentage of the theoretical maximal response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of the Maximal Response of NVA237 Doses on Forced Expiratory Volume in One Second at 12 Hours on Days 1 and 14 of Treatment</measure>
    <time_frame>Days 1 and 14</time_frame>
    <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Percentage of the maximal response of NVA237 doses on FEV1 at 12 hours was measured on days 1 and 14.
FEV1 was measured in response to all doses administered (see Outcome Measure #31). All FEV1 responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All FEV1 data are reported as a percentage of the theoretical maximal response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of the Maximal Response of NVA237 Doses on Peak Forced Expiratory Volume in One Second on Days 1, 7 and 14 of Treatment</measure>
    <time_frame>Days 1, 7, and 14</time_frame>
    <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Peak FEV1 is the maximum FEV1 recorded in a pre-determined period of time.
Percentage of the maximal response of NVA237 doses on Peak FEV1 was measured on days 1, 7 and 14 of treatment.
Peak FEV1 was measured in response to all doses administered (see Outcome Measure #32). All FEV1 responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All FEV1 data are reported as a percentage of the theoretical maximal response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of the Maximal Response of NVA237 Doses on Trough Forced Vital Capacity on Days 1, 7 and 14</measure>
    <time_frame>Days 1, 7 and 14</time_frame>
    <description>Percentage of the maximal response of NVA237 Doses on Trough Forced Vital Capacity (FVC) on Days 1, 7 and 14. FVC is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Trough FVC was assessed via spirometry. (see Outcome Measure #33).
Trough FVC is defined as the mean of the FVC values measured at 23 hours 15 mins and 23 hours 45 mins post-dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Daily Use of Rescue Medication by Treatment at Different Time Points</measure>
    <time_frame>Baseline, Weeks 1, 2, 3 and 4</time_frame>
    <description>Mean daily use of rescue medication by treatment and time points. Baseline was defined as the average of the total number of puffs of rescue medication during the week prior to treatment start, divided by the total number of days with non-missing rescue data during that week, then puffs were counted during weeks 1, 2, 3 and 4 postdose.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Trough Forced Expiratory Volume in One Second by Treatment at Day 28</measure>
    <time_frame>Day 28</time_frame>
    <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Spirometry was performed according to internationally accepted standards.
Trough FEV1 was defined as the mean of the 23 hour 15 minute and 23 hour 45 minute post-dose values.</description>
  </other_outcome>
  <other_outcome>
    <measure>Forced Expiratory Volume in One Second Area Under the Curve 0-24 Hours at Day 28 of Treatment</measure>
    <time_frame>5 min, 15 min, 1,2,3,4,6,8,10 hours, 11 hours 55 min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on day 28</time_frame>
    <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Spirometry was performed according to internationally accepted standards.
FEV1 Area Under the Curve (AUC) measurements were taken at 5 min, 15 min, 1,2,3,4,6,8,10 hours, 11 hours 55 min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on day 28. FEV1 AUC was calculated as the sum of trapezoids divided by the length of time.</description>
  </other_outcome>
  <other_outcome>
    <measure>Forced Expiratory Volume in One Second Area Under the Curve at Different Time Points (0-4 Hours, 0-8 Hours, 0-12 Hours, 12-24 Hours)</measure>
    <time_frame>5 min,15 min, 1,2,3,4,6,8,10 hours, 11 hours 55 min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on day 28</time_frame>
    <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Spirometry was performed according to internationally accepted standards.
FEV1 Area Under the Curve (AUC) measurements were taken at: 5 min,15 min, 1,2,3,4,6,8,10 hours, 11 hours 55 min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose). FEV1 AUC was calculated as the sum of trapezoids divided by the length of time.</description>
  </other_outcome>
  <other_outcome>
    <measure>Forced Expiratory Volume in One Second at 12 Hours on Day 28 of Treatment</measure>
    <time_frame>12 hours on day 28</time_frame>
    <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Spirometry was performed according to internationally accepted standards.</description>
  </other_outcome>
  <other_outcome>
    <measure>Peak Forced Expiratory Volume in One Second at Day 28 of Treatment</measure>
    <time_frame>25 min , 15 min pre-dose, 5 min, 15 min, 1 , 2 ,3 , 4 , 6 , 8 , 10 hours , 11 hour 55 min and 14 hour post-dose on day 28</time_frame>
    <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Spirometry was performed according to internationally accepted standards.
Peak FEV1 is the maximum FEV1 recorded in a pre-determined period of time. Measurements were taken at 25 min , 15 min pre-dose, 5 min, 15 min, 1 , 2 ,3 , 4 , 6 , 8 , 10 hours , 11 hour 55 min and 14 hour post-dose on day 28.</description>
  </other_outcome>
  <other_outcome>
    <measure>Trough Forced Vital Capacity After 28 Days of Treatment</measure>
    <time_frame>23 hours 15 mins and 23 hours 45 mins post-dose on Day 28</time_frame>
    <description>Forced Vital Capacity (FVC) after 28 days of treatment. FVC is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. FVC was assessed via spirometry. Trough FVC was defined as the mean of the FVC values measured at 23 hours 15 mins and 23 hours 45 mins post-dose.</description>
  </other_outcome>
  <other_outcome>
    <measure>Trough Forced Expiratory Volume in One Second at Days 1, 7 and 14</measure>
    <time_frame>23 hours 15 mins and 23 hours 45 mins post-dose on Days 1, 7 and 14</time_frame>
    <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Spirometry was performed according to internationally accepted standards.
Trough FEV1 was measured on Days 1, 7 and 14 of treatment. Trough FEV1 was defined as the mean of the FEV1 values measured at 23 hours 15 mins and 23 hours 45 mins post-dose.</description>
  </other_outcome>
  <other_outcome>
    <measure>Forced Expiratory Volume in One Second Area Under the Curve 0-24 Hours on Days 1 and 14 of Treatment</measure>
    <time_frame>5 min, 15 min, 1,2,3,4,6,8,10 hours, 11 hours 55 min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on days 1 and 14</time_frame>
    <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Spirometry was performed according to internationally accepted standards.
FEV1 Area Under the Curve (AUC) measurements were taken at 5 min, 15 min, 1,2,3,4,6,8,10 hours, 11 hours 55 min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on days 1 and 14 of treatment. FEV1 AUC was calculated as the sum of trapezoids divided by the length of time.</description>
  </other_outcome>
  <other_outcome>
    <measure>Forced Expiratory Volume in One Second Area Under the Curve 0-4 Hours on Days 1, 7 and 14 of Treatment</measure>
    <time_frame>5 min,15 min, 1,2,3,4 hours (postdose) on Days 1, 7 and 14</time_frame>
    <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Spirometry was performed according to internationally accepted standards.
FEV1 Area Under the Curve (AUC) measurements were taken at 5 min, 15 min, 1,2,3,4 hours (postdose) on days 1, 7 and 14 of treatment. FEV1 AUC was calculated as the sum of trapezoids divided by the length of time.</description>
  </other_outcome>
  <other_outcome>
    <measure>Forced Expiratory Volume in One Second of Area Under the Curve 0-8 Hours Days 1, 7, and 14</measure>
    <time_frame>at 5 min,15 min, 1,2,3,4,6,8 hours (postdose) on days 1, 7 and 14</time_frame>
    <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Percentage of the maximal response of NVA237 doses on FEV1 Area Under the Curve (AUC) 0-8 was calculated from measurements taken at 5 min,15 min, 1,2,3,4,6,8 hours (postdose) on days 1, 7, and 14. FEV1 AUC was calculated as the sum of trapezoids divided by the length of time.</description>
  </other_outcome>
  <other_outcome>
    <measure>Forced Expiratory Volume in One Second Area Under the Curve 0-12 Hours at Day 1 and 14 of Treatment</measure>
    <time_frame>5 min,15 min, 1,2,3,4,6,8,10 hours, 11h 55 min (postdose) on days 1 and 14</time_frame>
    <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Percentage of the maximal response of NVA237 doses was calculated on FEV1 Area Under the Curve (AUC) 0-12 hours from measurements taken at at 5 min,15 min, 1,2,3,4,6,8,10 hours, 11h 55 min (postdose) on days 1 and 14. FEV1 AUC was calculated as the sum of trapezoids divided by the length of time.</description>
  </other_outcome>
  <other_outcome>
    <measure>Forced Expiratory Volume in One Second of Area Under the Curve 12-24 Hours Over Days 1, and 14 of Treatment</measure>
    <time_frame>11 hours 55 min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on Days 1 and 14</time_frame>
    <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Percentage of the maximal response of NVA237 on FEV1 Area under the curve (AUC) 12-24 hours was calculated from measurements taken at 11 hours 55 min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on Days 1 and 14. FEV1 AUC was calculated as the sum of trapezoids divided by the length of time.</description>
  </other_outcome>
  <other_outcome>
    <measure>Forced Expiratory Volume in One Second at 12 Hours on Days 1 and 14 of Treatment</measure>
    <time_frame>Days 1 and 14</time_frame>
    <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Percentage of the maximal response of NVA237 doses on FEV1 at 12 hours was measured on days 1 and 14.</description>
  </other_outcome>
  <other_outcome>
    <measure>Peak Forced Expiratory Volume in One Second on Days 1, 7 and 14 of Treatment</measure>
    <time_frame>Days 1, 7, and 14</time_frame>
    <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Peak FEV1 is the maximum FEV1 recorded in a pre-determined period of time.
Percentage of the maximal response of NVA237 doses on Peak FEV1 was measured on days 1, 7 and 14 of treatment.</description>
  </other_outcome>
  <other_outcome>
    <measure>Trough Forced Vital Capacity on Days 1, 7 and 14</measure>
    <time_frame>Days 1, 7 and 14</time_frame>
    <description>Trough Forced Vital Capacity (FVC) on Days 1, 7 and 14. FVC is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. FVC was assessed via spirometry. (see Outcome Measure #23).
Trough FVC was defined as the mean of the 23 hour 15 minute and 23 hour 45 minute post-dose values.</description>
  </other_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">388</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>NVA237 12.5 µg q.d.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NVA237 12.5 µg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NVA237 25.0 µg q.d.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NVA237 25.0 µg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NVA237 12.5 µg b.i.d.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NVA237 12.5 µg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NVA237 50.0 µg q.d.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NVA237 50.0 µg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NVA237 25.0 µg b.i.d.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NVA237 25.0 µg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NVA237 100.0 µg q.d.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NVA237 100.0 µg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NVA237 50.0 µg b.i.d.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NVA237 50.0 µg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to NVA237 once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NVA237 12.5 µg once daily</intervention_name>
    <description>NVA237 12.5 µg via dry powder inhaler once daily for 28 days during either period 1 or during period 2.</description>
    <arm_group_label>NVA237 12.5 µg q.d.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NVA237 25.0 µg once daily</intervention_name>
    <description>NVA237 25.0 µg via dry powder inhaler once daily for 28 days during either period 1 or during period 2.</description>
    <arm_group_label>NVA237 25.0 µg q.d.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NVA237 12.5 µg twice daily</intervention_name>
    <description>NVA237 12.5 µg via dry powder inhaler twice daily for 28 days during either period 1 or during period 2.</description>
    <arm_group_label>NVA237 12.5 µg b.i.d.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NVA237 50.0 µg once daily</intervention_name>
    <description>NVA237 50.0 µg via dry powder inhaler once daily for 28 days during either period 1 or during period 2.</description>
    <arm_group_label>NVA237 50.0 µg q.d.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NVA237 25.0 µg twice daily</intervention_name>
    <description>NVA237 25.0 µg via dry powder inhaler twice daily for 28 days during either period 1 or during period 2.</description>
    <arm_group_label>NVA237 25.0 µg b.i.d.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NVA237 100.0 µg once daily</intervention_name>
    <description>NVA237 100.0 µg via dry powder inhaler once daily for 28 days during either period 1 or during period 2.</description>
    <arm_group_label>NVA237 100.0 µg q.d.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NVA237 50.0 µg twice daily</intervention_name>
    <description>NVA237 50.0 µg via dry powder inhaler twice daily for 28 days during either period 1 or during period 2.</description>
    <arm_group_label>NVA237 50.0 µg b.i.d.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to NVA237 once daily</intervention_name>
    <description>Placebo to NVA237 via dry powder inhaler once daily for 28 days during either period 1 or during period 2.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients age 40 years or more

          -  Diagnosis of Chronic Obstructive Lung Disease (COPD) (moderate to severe as classified
             by the Global Initiative for COPD (GOLD) Guidelines, 2008

          -  Smoking history of at least 10 pack-years

          -  Post-bronchodilator Forced Expiratory Volume in 1 second (FEV1) &lt;80% and ≥30% of the
             predicted normal value

          -  Post-bronchodilator FEV1/Forced Vital Capacity (FVC) &lt;0.7

          -  Symptomatic patients, according to daily electronic diary data between visit 2 (Day
             -8) and Visit 3 (Day 1), with a total score of 1 or more on at least 4 of the last 7
             days prior to visit 3

        Exclusion Criteria:

          -  Patients who have had a COPD exacerbation requiring systemic corticosteroids and/or
             antibiotics and/or hospitalization in the 6 weeks prior to the first visit

          -  Patients who have had a respiratory tract infection within 4 weeks prior to the first
             visit

          -  Patients with concomitant pulmonary disease

          -  Patients with diabetes Type I or uncontrolled diabetes Type II

          -  Any patient with lung cancer or a history of lung cancer

          -  Patients with a history of certain cardiovascular co-morbid conditions

          -  Patients with a history of asthma or a blood eosinophil count &gt;600/mm3 or onset of
             symptoms prior to 40 years

          -  Patients with eczema, known high IgE levels or a known positive skin prick test

          -  Patients participating in the active phase of a pulmonary rehabilitation programme

          -  Patients contraindicated for the treatment with anticholinergics, long and
             short-acting beta-2 agonists or sympathomimetic amines

          -  Patients with a history of alpha-1 anti-trypsin deficiency

          -  Patients on long term oxygen therapy (&gt;15hr per day)

          -  Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Genk</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Jambes</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Balassagyarmat</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Balatonfured</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Szolnok</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Torokbalint</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Almelo</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Harderwijk</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heerlen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Helmond</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Veldhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zutphen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Izabelin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>La Coruña</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ponferrada</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2010</study_first_submitted>
  <study_first_submitted_qc>May 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2010</study_first_posted>
  <results_first_submitted>January 23, 2013</results_first_submitted>
  <results_first_submitted_qc>March 19, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 15, 2014</results_first_posted>
  <disposition_first_submitted>October 24, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>October 24, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 26, 2011</disposition_first_posted>
  <last_update_submitted>March 3, 2015</last_update_submitted>
  <last_update_submitted_qc>March 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycopyrrolate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were randomized to 1 of 8 treatment groups during period 1; participants were then switched to a different treatment group during period 2 after a 7 days wash out. Each period lasted up to 29 days.</recruitment_details>
      <pre_assignment_details>For this crossover study, a participant is counted in 2 treatment groups</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Overall Study</title>
          <description>For the overall study, 388 participants were randomized and 1 non-randomized participant received drug in error and was discontinued. This participant was excluded from randomized number of patients but included in number of treated participants and in the safety set.
Out of the 388 participants randomized, 341 completed study treatment and 47 discontinued, including 3 misrandomized participants who did not receive any study medication.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="388">These participants were randomized to 2 different treatment sequences during period 1 and 2.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NVA237 12.5 ug q.d.</title>
              <participants_list>
                <participants group_id="P1" count="96">5 randomized and 2 misrandomized patients did not receive study drug, 80 completed, 9 discontinued.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NVA237 25 ug q.d.</title>
              <participants_list>
                <participants group_id="P1" count="99">3 randomized participants did not receive study drug, 91 completed treatment, 5 discontinued.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NVA237 12.5 ug b.i.d.</title>
              <participants_list>
                <participants group_id="P1" count="99">4 randomized participants did not receive study drug, 93 completed treatment, 2 discontinued.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NVA237 50 ug q.d.</title>
              <participants_list>
                <participants group_id="P1" count="96">4 randomized participants did not receive study drug, 89 completed treatment, 3 discontinued.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NVA237 25 ug b.i.d.</title>
              <participants_list>
                <participants group_id="P1" count="100">4 randomized participants did not receive study drug, 89 completed treatment, 7 discontinued.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NVA237 100 ug q.d.</title>
              <participants_list>
                <participants group_id="P1" count="98">2 randomized participants did not receive study drug, 92 completed treatment, 4 discontinued.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NVA237 50 ug b.i.d.</title>
              <participants_list>
                <participants group_id="P1" count="94">6 randomized and 1 misrandomized patients did not receive study drug, 82 completed, 5 discontinued.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Placebo</title>
              <participants_list>
                <participants group_id="P1" count="94">3 randomized participants did not receive study drug, 82 completed treatment, 5 discontinued.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="341">These participants completed both periods 1 and 2</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal lab value</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline/demographic measures are based on safety set</population>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
          <description>All participants in the safety set</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="386"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.2" spread="7.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Trough Forced Expiratory Volume in One Second for Once and Twice Daily Regimens of NVA237 for the Same Total Daily Dose of NVA237</title>
        <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer.
FEV1 was measured between dosing regimens (over the range 20 micrograms to 55 micrograms total daily dose) after 28 days of treatment.
Mean trough FEV1 was measured in response to all doses administered (12.5 µg q.d., 25.0 µg q.d., 12.5 µg b.i.d., 50 µg q.d., 25 µg b.i.d., 100 µg q.d., 50.0 µg b.i.d., and Placebo; see Outcome Measure # 19), and was used to compute modeled dose-response curves for once-daily and twice-daily regimens separately. The difference between those curves was computed at pre-specified theoretical doses (20 µg, 25 µg, 30 µg, 35 µg, 40 µg, 45 µg, 50 µg, and 55 µg) chosen at points likely to show the largest differences between the once-daily and twice-daily regimens. The theoretical responses to each dosing schedule separately and the difference between the once-daily and twice-daily regimens are represented below.</description>
        <time_frame>day 28</time_frame>
        <population>Full analysis set includes all randomized patients who received at least one dose of study drug and data available for analysis. Only patients with non-missing values were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Study</title>
            <description>A statistical modeling process was used to achieve the key objective. A set of 4 candidate models based on the Emax dose-response shape was derived plus their sigmoidal Emax counterparts (a total of 8 models) that describe the evolution of dose response over time. A model-averaging process was then employed to obtain response predictions as the weighted average of individual model predictions and confidence limits derived using a simulation-based procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Forced Expiratory Volume in One Second for Once and Twice Daily Regimens of NVA237 for the Same Total Daily Dose of NVA237</title>
          <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer.
FEV1 was measured between dosing regimens (over the range 20 micrograms to 55 micrograms total daily dose) after 28 days of treatment.
Mean trough FEV1 was measured in response to all doses administered (12.5 µg q.d., 25.0 µg q.d., 12.5 µg b.i.d., 50 µg q.d., 25 µg b.i.d., 100 µg q.d., 50.0 µg b.i.d., and Placebo; see Outcome Measure # 19), and was used to compute modeled dose-response curves for once-daily and twice-daily regimens separately. The difference between those curves was computed at pre-specified theoretical doses (20 µg, 25 µg, 30 µg, 35 µg, 40 µg, 45 µg, 50 µg, and 55 µg) chosen at points likely to show the largest differences between the once-daily and twice-daily regimens. The theoretical responses to each dosing schedule separately and the difference between the once-daily and twice-daily regimens are represented below.</description>
          <population>Full analysis set includes all randomized patients who received at least one dose of study drug and data available for analysis. Only patients with non-missing values were included.</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="385"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total daily dose 20 ug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.037" lower_limit="0.013" upper_limit="0.053"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total daily dose 25 ug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.037" lower_limit="0.013" upper_limit="0.052"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total daily dose 30 ug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.036" lower_limit="0.013" upper_limit="0.051"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total daily dose 35 ug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.035" lower_limit="0.013" upper_limit="0.050"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total daily dose 40 ug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.034" lower_limit="0.013" upper_limit="0.049"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total daily dose 45 ug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.033" lower_limit="0.013" upper_limit="0.047"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total daily dose 50 ug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.032" lower_limit="0.012" upper_limit="0.046"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total daily dose 55 ug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.031" lower_limit="0.012" upper_limit="0.045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of the Maximal Response of NVA237 Doses on Forced Expiratory Volume in One Second Area Under the Curve 0-24 Hours at Day 28 of Treatment</title>
        <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer.
Percentage of the maximal response of NVA237 doses on FEV1 Area Under the Curve (AUC) 0-24 hours at day 28 of treatment was calculated from measurements taken at 5 min, 15 min, 1,2,3,4,6,8,10 hours, 11 hours 55 min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on day 28.
AUC FEV1 was measured in response to all doses administered (see Outcome Measure #20). All FEV1 responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All FEV1 data are reported as a percentage of the theoretical maximal response.</description>
        <time_frame>5 min, 15 min, 1,2,3,4,6,8,10 hours, 11 hours 55 min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on day 28</time_frame>
        <population>Full analysis set includes all randomized patients who received at least one dose of study drug and data available for analysis. Only patients with non-missing values were included.</population>
        <group_list>
          <group group_id="O1">
            <title>NVA237 12.5 µg q.d.</title>
            <description>NVA237 12.5 µg once daily</description>
          </group>
          <group group_id="O2">
            <title>NVA237 25.0 µg q.d.</title>
            <description>NVA237 25.0 µg once daily</description>
          </group>
          <group group_id="O3">
            <title>NVA237 12.5 µg b.i.d.</title>
            <description>NVA237 12.5 µg twice daily</description>
          </group>
          <group group_id="O4">
            <title>NVA237 50.0 µg q.d.</title>
            <description>NVA237 50.0 µg once daily</description>
          </group>
          <group group_id="O5">
            <title>NVA237 25.0 µg b.i.d.</title>
            <description>NVA237 25.0 µg twice daily</description>
          </group>
          <group group_id="O6">
            <title>NVA237 100.0 µg q.d.</title>
            <description>NVA237 100.0 µg once daily</description>
          </group>
          <group group_id="O7">
            <title>NVA237 50.0 µg b.i.d.</title>
            <description>NVA237 50.0 µg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of the Maximal Response of NVA237 Doses on Forced Expiratory Volume in One Second Area Under the Curve 0-24 Hours at Day 28 of Treatment</title>
          <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer.
Percentage of the maximal response of NVA237 doses on FEV1 Area Under the Curve (AUC) 0-24 hours at day 28 of treatment was calculated from measurements taken at 5 min, 15 min, 1,2,3,4,6,8,10 hours, 11 hours 55 min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on day 28.
AUC FEV1 was measured in response to all doses administered (see Outcome Measure #20). All FEV1 responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All FEV1 data are reported as a percentage of the theoretical maximal response.</description>
          <population>Full analysis set includes all randomized patients who received at least one dose of study drug and data available for analysis. Only patients with non-missing values were included.</population>
          <units>Percentage of maximal response * hours</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="91"/>
                <count group_id="O4" value="90"/>
                <count group_id="O5" value="92"/>
                <count group_id="O6" value="91"/>
                <count group_id="O7" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.9" lower_limit="18.7" upper_limit="41.6"/>
                    <measurement group_id="O2" value="44.8" lower_limit="31.6" upper_limit="58.8"/>
                    <measurement group_id="O3" value="49.0" lower_limit="34.1" upper_limit="64.1"/>
                    <measurement group_id="O4" value="61.9" lower_limit="48.0" upper_limit="74.0"/>
                    <measurement group_id="O5" value="65.7" lower_limit="50.9" upper_limit="78.1"/>
                    <measurement group_id="O6" value="76.4" lower_limit="64.8" upper_limit="85.1"/>
                    <measurement group_id="O7" value="79.3" lower_limit="67.5" upper_limit="87.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Volume in One Second AUC 0-24 Hours for Once and Twice Daily Regimens of NVA237 for the Same Total Daily Dose of NVA237, After 28 Days of Treatment</title>
        <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer.
The Area Under the Curve (AUC) 0-24 hours FEV1 between dosing regimens over the range 20 micrograms to 55 micrograms total daily dose at -25 min,-15 min (predose); 5 min, 15 min, 1,2,3,4,6,8,10 hours, 11 hours 55 min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on day 28.
AUC 0-24 hours FEV1 was measured in response to all doses administered (12.5 µg q.d., 25.0 µg q.d., 12.5 µg b.i.d., 50 µg q.d., 25 µg b.i.d., 100 µg q.d., 50.0 µg b.i.d., and Placebo; see Outcome Measure # 20), and was used to compute modeled dose-response curves for once-daily and twice-daily regimens separately. The difference between those curves was computed at pre-specified theoretical doses (20 µg, 25 µg, 30 µg, 35 µg, 40 µg, 45 µg, 50 µg, and 55 µg) chosen at points likely to show the largest differences between the once-daily and twice-daily regimens.</description>
        <time_frame>-25 min,-15 min (predose); 5 min,15 min, 1,2,3,4,6,8,10 hours, 11 hours 55min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on day 28</time_frame>
        <population>Full analysis set includes all randomized patients who received at least one dose of study drug and data available for analysis. Only patients with non-missing values were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Study</title>
            <description>A statistical modeling process was used to achieve the key objective. A set of 4 candidate models based on the Emax dose-response shape was derived plus their sigmoidal Emax counterparts (a total of 8 models) that describe the evolution of dose response over time. A model-averaging process was then employed to obtain response predictions as the weighted average of individual model predictions and confidence limits derived using a simulation-based procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in One Second AUC 0-24 Hours for Once and Twice Daily Regimens of NVA237 for the Same Total Daily Dose of NVA237, After 28 Days of Treatment</title>
          <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer.
The Area Under the Curve (AUC) 0-24 hours FEV1 between dosing regimens over the range 20 micrograms to 55 micrograms total daily dose at -25 min,-15 min (predose); 5 min, 15 min, 1,2,3,4,6,8,10 hours, 11 hours 55 min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on day 28.
AUC 0-24 hours FEV1 was measured in response to all doses administered (12.5 µg q.d., 25.0 µg q.d., 12.5 µg b.i.d., 50 µg q.d., 25 µg b.i.d., 100 µg q.d., 50.0 µg b.i.d., and Placebo; see Outcome Measure # 20), and was used to compute modeled dose-response curves for once-daily and twice-daily regimens separately. The difference between those curves was computed at pre-specified theoretical doses (20 µg, 25 µg, 30 µg, 35 µg, 40 µg, 45 µg, 50 µg, and 55 µg) chosen at points likely to show the largest differences between the once-daily and twice-daily regimens.</description>
          <population>Full analysis set includes all randomized patients who received at least one dose of study drug and data available for analysis. Only patients with non-missing values were included.</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="385"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total daily dose 20 ug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.008" lower_limit="-0.008" upper_limit="0.023"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total daily dose 25 ug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.008" lower_limit="-0.008" upper_limit="0.024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total daily dose 30 ug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.008" lower_limit="-0.008" upper_limit="0.024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total daily dose 35 ug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.008" lower_limit="-0.008" upper_limit="0.023"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total daily dose 40 ug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.008" lower_limit="-0.008" upper_limit="0.023"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total daily dose 45 ug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.008" lower_limit="-0.008" upper_limit="0.022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total daily dose 50 ug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.008" lower_limit="-0.008" upper_limit="0.022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total daily dose 55 ug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.007" lower_limit="-0.007" upper_limit="0.021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of the Maximal Response of NVA237 Doses on Forced Expiratory Volume in One Second Area Under the Curve at Different Time Points (0-4 Hours, 0-8 Hours, 0-12 Hours, 12-24 Hours) on Day 28</title>
        <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer.
Percentage of the maximal response of NVA237 doses on FEV1 Area Under the Curve (AUC) 0-4 Hours, 0-8 Hours, 0-12 Hours, 12-24 Hours were calculated from measurements taken at: 5 min, 15 min, 1,2,3,4,6,8,10 hours, 11 hours 55 min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on day 28.
AUC FEV1 was measured in response to all doses administered (see Outcome Measure #21). All FEV1 responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All FEV1 data are reported as a percentage of the theoretical maximal response.</description>
        <time_frame>5 min,15 min, 1,2,3,4,6,8,10 hours, 11 hours 55 min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on day 28</time_frame>
        <population>Full analysis set includes all randomized patients who received at least one dose of study drug and data available for analysis. Only patients with non-missing values were included.</population>
        <group_list>
          <group group_id="O1">
            <title>NVA237 12.5 µg q.d.</title>
            <description>NVA237 12.5 µg once daily</description>
          </group>
          <group group_id="O2">
            <title>NVA237 25.0 µg q.d.</title>
            <description>NVA237 25.0 µg once daily</description>
          </group>
          <group group_id="O3">
            <title>NVA237 12.5 µg b.i.d.</title>
            <description>NVA237 12.5 µg twice daily</description>
          </group>
          <group group_id="O4">
            <title>NVA237 50.0 µg q.d.</title>
            <description>NVA237 50.0 µg once daily</description>
          </group>
          <group group_id="O5">
            <title>NVA237 25.0 µg b.i.d.</title>
            <description>NVA237 25.0 µg twice daily</description>
          </group>
          <group group_id="O6">
            <title>NVA237 100.0 µg q.d.</title>
            <description>NVA237 100.0 µg once daily</description>
          </group>
          <group group_id="O7">
            <title>NVA237 50.0 µg b.i.d.</title>
            <description>NVA237 50.0 µg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of the Maximal Response of NVA237 Doses on Forced Expiratory Volume in One Second Area Under the Curve at Different Time Points (0-4 Hours, 0-8 Hours, 0-12 Hours, 12-24 Hours) on Day 28</title>
          <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer.
Percentage of the maximal response of NVA237 doses on FEV1 Area Under the Curve (AUC) 0-4 Hours, 0-8 Hours, 0-12 Hours, 12-24 Hours were calculated from measurements taken at: 5 min, 15 min, 1,2,3,4,6,8,10 hours, 11 hours 55 min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on day 28.
AUC FEV1 was measured in response to all doses administered (see Outcome Measure #21). All FEV1 responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All FEV1 data are reported as a percentage of the theoretical maximal response.</description>
          <population>Full analysis set includes all randomized patients who received at least one dose of study drug and data available for analysis. Only patients with non-missing values were included.</population>
          <units>Percentage of maximal response* hours</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="91"/>
                <count group_id="O4" value="90"/>
                <count group_id="O5" value="92"/>
                <count group_id="O6" value="91"/>
                <count group_id="O7" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC 0-4h (n=82,90,91,89,92,91,82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.8" lower_limit="38.7" upper_limit="63.6"/>
                    <measurement group_id="O2" value="66.9" lower_limit="53.7" upper_limit="77.7"/>
                    <measurement group_id="O3" value="58.9" lower_limit="45.9" upper_limit="71.5"/>
                    <measurement group_id="O4" value="79.7" lower_limit="67.4" upper_limit="87.4"/>
                    <measurement group_id="O5" value="73.7" lower_limit="60.6" upper_limit="83.4"/>
                    <measurement group_id="O6" value="88.3" lower_limit="77.8" upper_limit="93.3"/>
                    <measurement group_id="O7" value="84.4" lower_limit="73.0" upper_limit="91.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC 0-8h (n=82,90,91,90,92,91,82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.8" lower_limit="33.2" upper_limit="58.8"/>
                    <measurement group_id="O2" value="62.8" lower_limit="49.9" upper_limit="74.1"/>
                    <measurement group_id="O3" value="55.5" lower_limit="42.0" upper_limit="68.4"/>
                    <measurement group_id="O4" value="77.1" lower_limit="66.6" upper_limit="85.1"/>
                    <measurement group_id="O5" value="71.4" lower_limit="59.1" upper_limit="81.2"/>
                    <measurement group_id="O6" value="87.1" lower_limit="79.9" upper_limit="91.9"/>
                    <measurement group_id="O7" value="83.3" lower_limit="74.3" upper_limit="89.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC 0-12h (n=82,90,91,90,92,91,82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.1" lower_limit="28.8" upper_limit="54.5"/>
                    <measurement group_id="O2" value="58.3" lower_limit="44.7" upper_limit="70.6"/>
                    <measurement group_id="O3" value="50.5" lower_limit="37.0" upper_limit="64.1"/>
                    <measurement group_id="O4" value="73.6" lower_limit="61.8" upper_limit="82.8"/>
                    <measurement group_id="O5" value="67.1" lower_limit="54.0" upper_limit="78.1"/>
                    <measurement group_id="O6" value="84.8" lower_limit="76.4" upper_limit="90.6"/>
                    <measurement group_id="O7" value="80.3" lower_limit="70.1" upper_limit="87.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC 12-24h (n=82,90,91,89,92,91,81)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.6" lower_limit="15.5" upper_limit="42.5"/>
                    <measurement group_id="O2" value="40.1" lower_limit="24.2" upper_limit="59.6"/>
                    <measurement group_id="O3" value="56.6" lower_limit="31.4" upper_limit="78.2"/>
                    <measurement group_id="O4" value="56.4" lower_limit="33.0" upper_limit="74.7"/>
                    <measurement group_id="O5" value="71.4" lower_limit="41.5" upper_limit="87.8"/>
                    <measurement group_id="O6" value="71.2" lower_limit="42.6" upper_limit="85.5"/>
                    <measurement group_id="O7" value="82.4" lower_limit="51.2" upper_limit="93.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of the Maximal Response of NVA237 Doses on Forced Expiratory Volume in One Second at 12 Hours at Day 28 of Treatment</title>
        <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Percentage of the maximal response within different doses/regimens of NVA237 was measured using FEV1 at 12 hours on day 28 of treatment.
FEV1 was measured in response to all doses administered (see Outcome Measure #22). All FEV1 responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All FEV1 data are reported as a percentage of the theoretical maximal response.</description>
        <time_frame>12 hours on day 28</time_frame>
        <population>Full analysis set includes all randomized patients who received at least one dose of study drug and data available for analysis. Only patients with non-missing values were included.</population>
        <group_list>
          <group group_id="O1">
            <title>NVA237 12.5 µg q.d.</title>
            <description>NVA237 12.5 µg once daily</description>
          </group>
          <group group_id="O2">
            <title>NVA237 25.0 µg q.d.</title>
            <description>NVA237 25.0 µg once daily</description>
          </group>
          <group group_id="O3">
            <title>NVA237 12.5 µg b.i.d.</title>
            <description>NVA237 12.5 µg twice daily</description>
          </group>
          <group group_id="O4">
            <title>NVA237 50.0 µg q.d.</title>
            <description>NVA237 50.0 µg once daily</description>
          </group>
          <group group_id="O5">
            <title>NVA237 25.0 µg b.i.d.</title>
            <description>NVA237 25.0 µg twice daily</description>
          </group>
          <group group_id="O6">
            <title>NVA237 100.0 µg q.d.</title>
            <description>NVA237 100.0 µg once daily</description>
          </group>
          <group group_id="O7">
            <title>NVA237 50.0 µg b.i.d.</title>
            <description>NVA237 50.0 µg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of the Maximal Response of NVA237 Doses on Forced Expiratory Volume in One Second at 12 Hours at Day 28 of Treatment</title>
          <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Percentage of the maximal response within different doses/regimens of NVA237 was measured using FEV1 at 12 hours on day 28 of treatment.
FEV1 was measured in response to all doses administered (see Outcome Measure #22). All FEV1 responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All FEV1 data are reported as a percentage of the theoretical maximal response.</description>
          <population>Full analysis set includes all randomized patients who received at least one dose of study drug and data available for analysis. Only patients with non-missing values were included.</population>
          <units>Percentage of maximal response</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="91"/>
                <count group_id="O4" value="85"/>
                <count group_id="O5" value="87"/>
                <count group_id="O6" value="88"/>
                <count group_id="O7" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.1" lower_limit="14.7" upper_limit="44.6"/>
                    <measurement group_id="O2" value="42.7" lower_limit="25.7" upper_limit="61.7"/>
                    <measurement group_id="O3" value="35.5" lower_limit="20.4" upper_limit="54.0"/>
                    <measurement group_id="O4" value="59.8" lower_limit="40.9" upper_limit="76.3"/>
                    <measurement group_id="O5" value="52.4" lower_limit="33.9" upper_limit="70.2"/>
                    <measurement group_id="O6" value="74.9" lower_limit="58.0" upper_limit="86.6"/>
                    <measurement group_id="O7" value="68.7" lower_limit="50.7" upper_limit="82.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of the Maximal Response of NVA237 Doses on Peak Forced Expiratory Volume in One Second at Day 28 of Treatment</title>
        <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Peak FEV1 is the maximum FEV1 recorded in a pre-determined period of time.
Percentage of the maximal response of NVA237 within different doses/regimens of NVA237 on Peak FEV1 was measured at day 28 of treatment.
Peak FEV1 was measured in response to all doses administered (see Outcome Measure #23). All FEV1 responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All FEV1 data are reported as a percentage of the theoretical maximal response.</description>
        <time_frame>day 28</time_frame>
        <population>Full analysis set includes all randomized patients who received at least one dose of study drug and data available for analysis. Only patients with non-missing values were included.</population>
        <group_list>
          <group group_id="O1">
            <title>NVA237 12.5 µg q.d.</title>
            <description>NVA237 12.5 µg once daily</description>
          </group>
          <group group_id="O2">
            <title>NVA237 25.0 µg q.d.</title>
            <description>NVA237 25.0 µg once daily</description>
          </group>
          <group group_id="O3">
            <title>NVA237 12.5 µg b.i.d.</title>
            <description>NVA237 12.5 µg twice daily</description>
          </group>
          <group group_id="O4">
            <title>NVA237 50.0 µg q.d.</title>
            <description>NVA237 50.0 µg once daily</description>
          </group>
          <group group_id="O5">
            <title>NVA237 25.0 µg b.i.d.</title>
            <description>NVA237 25.0 µg twice daily</description>
          </group>
          <group group_id="O6">
            <title>NVA237 100.0 µg q.d.</title>
            <description>NVA237 100.0 µg once daily</description>
          </group>
          <group group_id="O7">
            <title>NVA237 50.0 µg b.i.d.</title>
            <description>NVA237 50.0 µg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of the Maximal Response of NVA237 Doses on Peak Forced Expiratory Volume in One Second at Day 28 of Treatment</title>
          <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Peak FEV1 is the maximum FEV1 recorded in a pre-determined period of time.
Percentage of the maximal response of NVA237 within different doses/regimens of NVA237 on Peak FEV1 was measured at day 28 of treatment.
Peak FEV1 was measured in response to all doses administered (see Outcome Measure #23). All FEV1 responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All FEV1 data are reported as a percentage of the theoretical maximal response.</description>
          <population>Full analysis set includes all randomized patients who received at least one dose of study drug and data available for analysis. Only patients with non-missing values were included.</population>
          <units>Percentage of maximal response</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="91"/>
                <count group_id="O4" value="89"/>
                <count group_id="O5" value="92"/>
                <count group_id="O6" value="91"/>
                <count group_id="O7" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.3" lower_limit="41.2" upper_limit="65.5"/>
                    <measurement group_id="O2" value="69.2" lower_limit="56.7" upper_limit="79.2"/>
                    <measurement group_id="O3" value="61.1" lower_limit="48.2" upper_limit="73.4"/>
                    <measurement group_id="O4" value="81.5" lower_limit="71.1" upper_limit="88.4"/>
                    <measurement group_id="O5" value="75.6" lower_limit="63.4" upper_limit="84.7"/>
                    <measurement group_id="O6" value="89.6" lower_limit="82.4" upper_limit="93.9"/>
                    <measurement group_id="O7" value="85.8" lower_limit="76.5" upper_limit="91.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of the Maximal Response of NVA237 Doses on Forced Vital Capacity at Day 28 of Treatment</title>
        <description>Percentage of the maximal response of NVA237 within different doses/regimens of NVA237 on Forced Vital Capacity (FVC) was measured at day 28 of treatment. FVC is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible.
FVC at day 28 of treatment was measured via spirometry (see Outcome Measure #24). All FVC responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All FVC data are reported as a percentage of the theoretical maximal response.</description>
        <time_frame>day 28</time_frame>
        <population>Full analysis set includes all randomized patients who received at least one dose of study drug and data available for analysis. Only patients with non-missing values were included.</population>
        <group_list>
          <group group_id="O1">
            <title>NVA237 12.5 µg q.d.</title>
            <description>NVA237 12.5 µg once daily</description>
          </group>
          <group group_id="O2">
            <title>NVA237 25.0 µg q.d.</title>
            <description>NVA237 25.0 µg once daily</description>
          </group>
          <group group_id="O3">
            <title>NVA237 12.5 µg b.i.d.</title>
            <description>NVA237 12.5 µg twice daily</description>
          </group>
          <group group_id="O4">
            <title>NVA237 50.0 µg q.d.</title>
            <description>NVA237 50.0 µg once daily</description>
          </group>
          <group group_id="O5">
            <title>NVA237 25.0 µg b.i.d.</title>
            <description>NVA237 25.0 µg twice daily</description>
          </group>
          <group group_id="O6">
            <title>NVA237 100.0 µg q.d.</title>
            <description>NVA237 100.0 µg once daily</description>
          </group>
          <group group_id="O7">
            <title>NVA237 50.0 µg b.i.d.</title>
            <description>NVA237 50.0 µg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of the Maximal Response of NVA237 Doses on Forced Vital Capacity at Day 28 of Treatment</title>
          <description>Percentage of the maximal response of NVA237 within different doses/regimens of NVA237 on Forced Vital Capacity (FVC) was measured at day 28 of treatment. FVC is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible.
FVC at day 28 of treatment was measured via spirometry (see Outcome Measure #24). All FVC responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All FVC data are reported as a percentage of the theoretical maximal response.</description>
          <population>Full analysis set includes all randomized patients who received at least one dose of study drug and data available for analysis. Only patients with non-missing values were included.</population>
          <units>Percentage of maximal response</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="90"/>
                <count group_id="O4" value="88"/>
                <count group_id="O5" value="87"/>
                <count group_id="O6" value="90"/>
                <count group_id="O7" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.3" lower_limit="11.3" upper_limit="45.3"/>
                    <measurement group_id="O2" value="37.4" lower_limit="19.8" upper_limit="62.7"/>
                    <measurement group_id="O3" value="53.6" lower_limit="26.5" upper_limit="81.2"/>
                    <measurement group_id="O4" value="54.0" lower_limit="30.9" upper_limit="77.2"/>
                    <measurement group_id="O5" value="69.3" lower_limit="38.6" upper_limit="89.7"/>
                    <measurement group_id="O6" value="69.7" lower_limit="43.6" upper_limit="87.2"/>
                    <measurement group_id="O7" value="81.4" lower_limit="52.5" upper_limit="94.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of the Maximal Response of NVA237 Doses on Trough Forced Expiratory Volume in One Second at Days 1, 7 and 14</title>
        <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Percentage of the maximal response of NVA237 doses on Trough FEV1 was measured on Days 1, 7 and 14.
Through FEV1 was measured in response to all doses administered (see Outcome Measure #25). All FEV1 responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All FEV1 data are reported as a percentage of the theoretical maximal response.
Trough FEV1 was defined as the mean of the 23 hour 15 minute and 23 hour 45 minute post-dose values.</description>
        <time_frame>Days 1, 7 and 14</time_frame>
        <population>Full analysis set includes all randomized patients who received at least one dose of study drug and data available for analysis. Only patients with non-missing values were included.</population>
        <group_list>
          <group group_id="O1">
            <title>NVA237 12.5 µg q.d.</title>
            <description>NVA237 12.5 µg once daily</description>
          </group>
          <group group_id="O2">
            <title>NVA237 25.0 µg q.d.</title>
            <description>NVA237 25.0 µg once daily</description>
          </group>
          <group group_id="O3">
            <title>NVA237 12.5 µg b.i.d.</title>
            <description>NVA237 12.5 µg twice daily</description>
          </group>
          <group group_id="O4">
            <title>NVA237 50.0 µg q.d.</title>
            <description>NVA237 50.0 µg once daily</description>
          </group>
          <group group_id="O5">
            <title>NVA237 25.0 µg b.i.d.</title>
            <description>NVA237 25.0 µg twice daily</description>
          </group>
          <group group_id="O6">
            <title>NVA237 100.0 µg q.d.</title>
            <description>NVA237 100.0 µg once daily</description>
          </group>
          <group group_id="O7">
            <title>NVA237 50.0 µg b.i.d.</title>
            <description>NVA237 50.0 µg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of the Maximal Response of NVA237 Doses on Trough Forced Expiratory Volume in One Second at Days 1, 7 and 14</title>
          <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Percentage of the maximal response of NVA237 doses on Trough FEV1 was measured on Days 1, 7 and 14.
Through FEV1 was measured in response to all doses administered (see Outcome Measure #25). All FEV1 responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All FEV1 data are reported as a percentage of the theoretical maximal response.
Trough FEV1 was defined as the mean of the 23 hour 15 minute and 23 hour 45 minute post-dose values.</description>
          <population>Full analysis set includes all randomized patients who received at least one dose of study drug and data available for analysis. Only patients with non-missing values were included.</population>
          <units>Percentage of maximal response</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="92"/>
                <count group_id="O3" value="91"/>
                <count group_id="O4" value="91"/>
                <count group_id="O5" value="95"/>
                <count group_id="O6" value="94"/>
                <count group_id="O7" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (n= 88,92,91, 90, 94, 94, 87)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.5" lower_limit="17.5" upper_limit="45.3"/>
                    <measurement group_id="O2" value="43.8" lower_limit="27.8" upper_limit="62.3"/>
                    <measurement group_id="O3" value="63.3" lower_limit="37.9" upper_limit="82.5"/>
                    <measurement group_id="O4" value="60.1" lower_limit="38.2" upper_limit="76.8"/>
                    <measurement group_id="O5" value="76.7" lower_limit="49.3" upper_limit="90.5"/>
                    <measurement group_id="O6" value="74.3" lower_limit="48.6" upper_limit="86.9"/>
                    <measurement group_id="O7" value="86.2" lower_limit="59.8" upper_limit="95.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 (n= 87,92,90, 91, 95, 93, 85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.1" lower_limit="16.3" upper_limit="44.3"/>
                    <measurement group_id="O2" value="42.0" lower_limit="26.3" upper_limit="61.4"/>
                    <measurement group_id="O3" value="61.6" lower_limit="36.4" upper_limit="82.1"/>
                    <measurement group_id="O4" value="58.5" lower_limit="37.3" upper_limit="76.1"/>
                    <measurement group_id="O5" value="75.5" lower_limit="48.3" upper_limit="90.1"/>
                    <measurement group_id="O6" value="73.0" lower_limit="48.7" upper_limit="86.4"/>
                    <measurement group_id="O7" value="85.4" lower_limit="59.8" upper_limit="94.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 (n= 85,90,91, 88, 94, 93, 81)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.1" lower_limit="16.4" upper_limit="44.3"/>
                    <measurement group_id="O2" value="42.0" lower_limit="26.4" upper_limit="61.4"/>
                    <measurement group_id="O3" value="61.6" lower_limit="36.6" upper_limit="82.1"/>
                    <measurement group_id="O4" value="58.5" lower_limit="37.4" upper_limit="76.1"/>
                    <measurement group_id="O5" value="75.5" lower_limit="48.5" upper_limit="90.2"/>
                    <measurement group_id="O6" value="73.0" lower_limit="48.8" upper_limit="86.5"/>
                    <measurement group_id="O7" value="85.4" lower_limit="60.1" upper_limit="94.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of the Maximal Effect of NVA237 Doses on Forced Expiratory Volume in One Second Area Under the Curve 0-24 Hours on Days 1 and 14 of Treatment</title>
        <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer.
Percentage of the maximal response of NVA237 doses on FEV1 Area Under the Curve (AUC) 0-24 hours, was calculated from measurements taken at 5 min,15 min, 1,2,3,4,6,8,10 hours, 11 hours 55min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on days 1 and 14.
FEV1 AUC 0-24 hours was measured on days 1 and 14 of treatment in response to all doses administered (see Outcome Measure #26). All FEV1 responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All FEV1 data are reported as a percentage of the theoretical maximal response.</description>
        <time_frame>5 min,15 min, 1,2,3,4,6,8,10 hours, 11 hours 55min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on days 1 and 14</time_frame>
        <population>Full analysis set includes all randomized patients who received at least one dose of study drug and data available for analysis. Only patients with non-missing values were included.</population>
        <group_list>
          <group group_id="O1">
            <title>NVA237 12.5 µg q.d.</title>
            <description>NVA237 12.5 µg once daily</description>
          </group>
          <group group_id="O2">
            <title>NVA237 25.0 µg q.d.</title>
            <description>NVA237 25.0 µg once daily</description>
          </group>
          <group group_id="O3">
            <title>NVA237 12.5 µg b.i.d.</title>
            <description>NVA237 12.5 µg twice daily</description>
          </group>
          <group group_id="O4">
            <title>NVA237 50.0 µg q.d.</title>
            <description>NVA237 50.0 µg once daily</description>
          </group>
          <group group_id="O5">
            <title>NVA237 25.0 µg b.i.d.</title>
            <description>NVA237 25.0 µg twice daily</description>
          </group>
          <group group_id="O6">
            <title>NVA237 100.0 µg q.d.</title>
            <description>NVA237 100.0 µg once daily</description>
          </group>
          <group group_id="O7">
            <title>NVA237 50.0 µg b.i.d.</title>
            <description>NVA237 50.0 µg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of the Maximal Effect of NVA237 Doses on Forced Expiratory Volume in One Second Area Under the Curve 0-24 Hours on Days 1 and 14 of Treatment</title>
          <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer.
Percentage of the maximal response of NVA237 doses on FEV1 Area Under the Curve (AUC) 0-24 hours, was calculated from measurements taken at 5 min,15 min, 1,2,3,4,6,8,10 hours, 11 hours 55min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on days 1 and 14.
FEV1 AUC 0-24 hours was measured on days 1 and 14 of treatment in response to all doses administered (see Outcome Measure #26). All FEV1 responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All FEV1 data are reported as a percentage of the theoretical maximal response.</description>
          <population>Full analysis set includes all randomized patients who received at least one dose of study drug and data available for analysis. Only patients with non-missing values were included.</population>
          <units>Percentage of maximal response* hours</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="94"/>
                <count group_id="O3" value="93"/>
                <count group_id="O4" value="92"/>
                <count group_id="O5" value="96"/>
                <count group_id="O6" value="96"/>
                <count group_id="O7" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (n= 89,94,93,92,96,96,87)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.3" lower_limit="25.3" upper_limit="53.4"/>
                    <measurement group_id="O2" value="55.4" lower_limit="40.4" upper_limit="69.6"/>
                    <measurement group_id="O3" value="59.5" lower_limit="42.8" upper_limit="74.2"/>
                    <measurement group_id="O4" value="71.3" lower_limit="57.5" upper_limit="82.1"/>
                    <measurement group_id="O5" value="74.6" lower_limit="60.0" upper_limit="85.2"/>
                    <measurement group_id="O6" value="83.2" lower_limit="73.0" upper_limit="90.2"/>
                    <measurement group_id="O7" value="85.4" lower_limit="75.0" upper_limit="92.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 (n= 86,92,91,91,95,93,84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.9" lower_limit="18.7" upper_limit="41.6"/>
                    <measurement group_id="O2" value="44.8" lower_limit="31.6" upper_limit="58.8"/>
                    <measurement group_id="O3" value="49.0" lower_limit="34.1" upper_limit="64.1"/>
                    <measurement group_id="O4" value="61.9" lower_limit="48.0" upper_limit="74.0"/>
                    <measurement group_id="O5" value="65.7" lower_limit="50.9" upper_limit="78.1"/>
                    <measurement group_id="O6" value="76.4" lower_limit="64.8" upper_limit="85.1"/>
                    <measurement group_id="O7" value="79.3" lower_limit="67.5" upper_limit="87.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of the Maximal Response of NVA237 Doses on Forced Expiratory Volume in One Second Area Under the Curve 0-4 Hours on Days 1, 7 and 14 of Treatment</title>
        <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer.
Percentage of the maximal response of NVA237 doses on FEV1 Area Under the Curve (AUC) 0-4 hours was calculated from measurements taken at 5 min,15 min, 1,2,3,4 hours (postdose) on Days 1, 7 and 14, in response to all doses administered (see Outcome Measure #27).
All AUC FEV1 responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All FEV1 data are reported as a percentage of the theoretical maximal response.</description>
        <time_frame>5 min,15 min, 1,2,3,4 hours (postdose) on Days 1, 7 and 14</time_frame>
        <population>Full analysis set includes all randomized patients who received at least one dose of study drug and data available for analysis. Only patients with non-missing values were included.</population>
        <group_list>
          <group group_id="O1">
            <title>NVA237 12.5 µg q.d.</title>
            <description>NVA237 12.5 µg once daily</description>
          </group>
          <group group_id="O2">
            <title>NVA237 25.0 µg q.d.</title>
            <description>NVA237 25.0 µg once daily</description>
          </group>
          <group group_id="O3">
            <title>NVA237 12.5 µg b.i.d.</title>
            <description>NVA237 12.5 µg twice daily</description>
          </group>
          <group group_id="O4">
            <title>NVA237 50.0 µg q.d.</title>
            <description>NVA237 50.0 µg once daily</description>
          </group>
          <group group_id="O5">
            <title>NVA237 25.0 µg b.i.d.</title>
            <description>NVA237 25.0 µg twice daily</description>
          </group>
          <group group_id="O6">
            <title>NVA237 100.0 µg q.d.</title>
            <description>NVA237 100.0 µg once daily</description>
          </group>
          <group group_id="O7">
            <title>NVA237 50.0 µg b.i.d.</title>
            <description>NVA237 50.0 µg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of the Maximal Response of NVA237 Doses on Forced Expiratory Volume in One Second Area Under the Curve 0-4 Hours on Days 1, 7 and 14 of Treatment</title>
          <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer.
Percentage of the maximal response of NVA237 doses on FEV1 Area Under the Curve (AUC) 0-4 hours was calculated from measurements taken at 5 min,15 min, 1,2,3,4 hours (postdose) on Days 1, 7 and 14, in response to all doses administered (see Outcome Measure #27).
All AUC FEV1 responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All FEV1 data are reported as a percentage of the theoretical maximal response.</description>
          <population>Full analysis set includes all randomized patients who received at least one dose of study drug and data available for analysis. Only patients with non-missing values were included.</population>
          <units>Percentage of maximal response* hours</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="94"/>
                <count group_id="O3" value="93"/>
                <count group_id="O4" value="92"/>
                <count group_id="O5" value="96"/>
                <count group_id="O6" value="96"/>
                <count group_id="O7" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (n=89,94,93,91,96,96,86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.4" lower_limit="44.4" upper_limit="71.8"/>
                    <measurement group_id="O2" value="73.2" lower_limit="59.1" upper_limit="83.6"/>
                    <measurement group_id="O3" value="66.1" lower_limit="51.6" upper_limit="78.6"/>
                    <measurement group_id="O4" value="84.1" lower_limit="72.0" upper_limit="91.1"/>
                    <measurement group_id="O5" value="79.1" lower_limit="65.6" upper_limit="88.0"/>
                    <measurement group_id="O6" value="91.1" lower_limit="81.5" upper_limit="95.3"/>
                    <measurement group_id="O7" value="88.0" lower_limit="77.1" upper_limit="93.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 (n=87,93,90,92,95,94,85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.8" lower_limit="38.7" upper_limit="63.6"/>
                    <measurement group_id="O2" value="66.9" lower_limit="53.7" upper_limit="77.7"/>
                    <measurement group_id="O3" value="58.9" lower_limit="45.9" upper_limit="71.5"/>
                    <measurement group_id="O4" value="79.7" lower_limit="67.4" upper_limit="87.4"/>
                    <measurement group_id="O5" value="73.7" lower_limit="60.6" upper_limit="83.4"/>
                    <measurement group_id="O6" value="88.3" lower_limit="77.8" upper_limit="93.3"/>
                    <measurement group_id="O7" value="84.4" lower_limit="73.0" upper_limit="91.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 (n=86,92,91,91,95,93,84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.8" lower_limit="38.7" upper_limit="63.6"/>
                    <measurement group_id="O2" value="66.9" lower_limit="53.7" upper_limit="77.7"/>
                    <measurement group_id="O3" value="58.9" lower_limit="45.9" upper_limit="71.5"/>
                    <measurement group_id="O4" value="79.7" lower_limit="67.4" upper_limit="87.4"/>
                    <measurement group_id="O5" value="73.7" lower_limit="60.6" upper_limit="83.4"/>
                    <measurement group_id="O6" value="88.3" lower_limit="77.8" upper_limit="93.3"/>
                    <measurement group_id="O7" value="84.4" lower_limit="73.0" upper_limit="91.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of the Maximal Response of NVA237 Doses on Forced Expiratory Volume in One Second of Area Under the Curve 0-8 Hours Days 1, 7, and 14</title>
        <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Percentage of the maximal response of NVA237 doses on FEV1 Area Under the Curve (AUC) 0-8 was calculated from measurements taken at 5 min,15 min, 1,2,3,4,6,8 hours (postdose) on days 1, 7, and 14.
AUC FEV1 was measured in response to all doses administered (see Outcome Measure #28). All FEV1 responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All FEV1 data are reported as a percentage of the theoretical maximal response.</description>
        <time_frame>at 5 min,15 min, 1,2,3,4,6,8 hours (postdose) on days 1, 7 and 14</time_frame>
        <population>Full analysis set includes all randomized patients who received at least one dose of study drug and data available for analysis. Only patients with non-missing values were included.</population>
        <group_list>
          <group group_id="O1">
            <title>NVA237 12.5 µg q.d.</title>
            <description>NVA237 12.5 µg once daily</description>
          </group>
          <group group_id="O2">
            <title>NVA237 25.0 µg q.d.</title>
            <description>NVA237 25.0 µg once daily</description>
          </group>
          <group group_id="O3">
            <title>NVA237 12.5 µg b.i.d.</title>
            <description>NVA237 12.5 µg twice daily</description>
          </group>
          <group group_id="O4">
            <title>NVA237 50.0 µg q.d.</title>
            <description>NVA237 50.0 µg once daily</description>
          </group>
          <group group_id="O5">
            <title>NVA237 25.0 µg b.i.d.</title>
            <description>NVA237 25.0 µg twice daily</description>
          </group>
          <group group_id="O6">
            <title>NVA237 100.0 µg q.d.</title>
            <description>NVA237 100.0 µg once daily</description>
          </group>
          <group group_id="O7">
            <title>NVA237 50.0 µg b.i.d.</title>
            <description>NVA237 50.0 µg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of the Maximal Response of NVA237 Doses on Forced Expiratory Volume in One Second of Area Under the Curve 0-8 Hours Days 1, 7, and 14</title>
          <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Percentage of the maximal response of NVA237 doses on FEV1 Area Under the Curve (AUC) 0-8 was calculated from measurements taken at 5 min,15 min, 1,2,3,4,6,8 hours (postdose) on days 1, 7, and 14.
AUC FEV1 was measured in response to all doses administered (see Outcome Measure #28). All FEV1 responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All FEV1 data are reported as a percentage of the theoretical maximal response.</description>
          <population>Full analysis set includes all randomized patients who received at least one dose of study drug and data available for analysis. Only patients with non-missing values were included.</population>
          <units>Percentage of maximal response* hours</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="94"/>
                <count group_id="O3" value="93"/>
                <count group_id="O4" value="92"/>
                <count group_id="O5" value="96"/>
                <count group_id="O6" value="96"/>
                <count group_id="O7" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (n=89, 94, 93, 91, 96, 96, 87)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.2" lower_limit="40.1" upper_limit="67.8"/>
                    <measurement group_id="O2" value="70.3" lower_limit="57.2" upper_limit="80.8"/>
                    <measurement group_id="O3" value="63.6" lower_limit="49.0" upper_limit="76.3"/>
                    <measurement group_id="O4" value="82.6" lower_limit="72.8" upper_limit="89.4"/>
                    <measurement group_id="O5" value="77.8" lower_limit="65.8" upper_limit="86.5"/>
                    <measurement group_id="O6" value="90.5" lower_limit="84.3" upper_limit="94.4"/>
                    <measurement group_id="O7" value="87.5" lower_limit="79.4" upper_limit="92.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 (n= 87, 93, 91, 92, 95, 94, 85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.8" lower_limit="33.2" upper_limit="58.8"/>
                    <measurement group_id="O2" value="62.8" lower_limit="49.9" upper_limit="74.1"/>
                    <measurement group_id="O3" value="55.5" lower_limit="42.0" upper_limit="68.4"/>
                    <measurement group_id="O4" value="77.1" lower_limit="66.6" upper_limit="85.1"/>
                    <measurement group_id="O5" value="71.4" lower_limit="59.1" upper_limit="81.2"/>
                    <measurement group_id="O6" value="87.1" lower_limit="79.9" upper_limit="91.9"/>
                    <measurement group_id="O7" value="83.3" lower_limit="74.3" upper_limit="89.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 (n=86, 92, 91, 91, 95, 93, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.8" lower_limit="33.2" upper_limit="58.8"/>
                    <measurement group_id="O2" value="62.8" lower_limit="49.9" upper_limit="74.1"/>
                    <measurement group_id="O3" value="55.5" lower_limit="42.0" upper_limit="68.4"/>
                    <measurement group_id="O4" value="77.1" lower_limit="66.6" upper_limit="85.1"/>
                    <measurement group_id="O5" value="71.4" lower_limit="59.1" upper_limit="81.2"/>
                    <measurement group_id="O6" value="87.1" lower_limit="79.9" upper_limit="91.9"/>
                    <measurement group_id="O7" value="83.3" lower_limit="74.3" upper_limit="89.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of the Maximal Response of NVA237 Doses on Forced Expiratory Volume in One Second Area Under the Curve 0-12 Hours at Day 1 and 14 of Treatment</title>
        <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Percentage of the maximal response of NVA237 doses was calculated on FEV1 Area Under the Curve (AUC) 0-12 hours from measurements taken at at 5 min,15 min, 1,2,3,4,6,8,10 hours, 11h 55 min (postdose) on days 1 and 14 in response to all doses administered (see Outcome Measure #29).
All AUC FEV1 responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All FEV1 data are reported as a percentage of the theoretical maximal response.</description>
        <time_frame>5 min,15 min, 1,2,3,4,6,8,10 hours, 11h 55 min (postdose) on days 1 and 14</time_frame>
        <population>Full analysis set includes all randomized patients who received at least one dose of study drug and data available for analysis. Only patients with non-missing values were included.</population>
        <group_list>
          <group group_id="O1">
            <title>NVA237 12.5 µg q.d.</title>
            <description>NVA237 12.5 µg once daily</description>
          </group>
          <group group_id="O2">
            <title>NVA237 25.0 µg q.d.</title>
            <description>NVA237 25.0 µg once daily</description>
          </group>
          <group group_id="O3">
            <title>NVA237 12.5 µg b.i.d.</title>
            <description>NVA237 12.5 µg twice daily</description>
          </group>
          <group group_id="O4">
            <title>NVA237 50.0 µg q.d.</title>
            <description>NVA237 50.0 µg once daily</description>
          </group>
          <group group_id="O5">
            <title>NVA237 25.0 µg b.i.d.</title>
            <description>NVA237 25.0 µg twice daily</description>
          </group>
          <group group_id="O6">
            <title>NVA237 100.0 µg q.d.</title>
            <description>NVA237 100.0 µg once daily</description>
          </group>
          <group group_id="O7">
            <title>NVA237 50.0 µg b.i.d.</title>
            <description>NVA237 50.0 µg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of the Maximal Response of NVA237 Doses on Forced Expiratory Volume in One Second Area Under the Curve 0-12 Hours at Day 1 and 14 of Treatment</title>
          <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Percentage of the maximal response of NVA237 doses was calculated on FEV1 Area Under the Curve (AUC) 0-12 hours from measurements taken at at 5 min,15 min, 1,2,3,4,6,8,10 hours, 11h 55 min (postdose) on days 1 and 14 in response to all doses administered (see Outcome Measure #29).
All AUC FEV1 responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All FEV1 data are reported as a percentage of the theoretical maximal response.</description>
          <population>Full analysis set includes all randomized patients who received at least one dose of study drug and data available for analysis. Only patients with non-missing values were included.</population>
          <units>Percentage of maximal response* hours</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="94"/>
                <count group_id="O3" value="93"/>
                <count group_id="O4" value="91"/>
                <count group_id="O5" value="96"/>
                <count group_id="O6" value="96"/>
                <count group_id="O7" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (n=89, 94, 93, 91, 96, 96, 87)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.5" lower_limit="35.5" upper_limit="63.6"/>
                    <measurement group_id="O2" value="66.2" lower_limit="52.4" upper_limit="77.8"/>
                    <measurement group_id="O3" value="58.8" lower_limit="44.0" upper_limit="72.3"/>
                    <measurement group_id="O4" value="79.6" lower_limit="68.7" upper_limit="87.5"/>
                    <measurement group_id="O5" value="74.1" lower_limit="61.1" upper_limit="83.9"/>
                    <measurement group_id="O6" value="88.7" lower_limit="81.5" upper_limit="93.3"/>
                    <measurement group_id="O7" value="85.1" lower_limit="75.9" upper_limit="91.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 (n=86, 92, 91, 91, 95, 93, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.1" lower_limit="28.8" upper_limit="54.5"/>
                    <measurement group_id="O2" value="58.3" lower_limit="44.7" upper_limit="70.6"/>
                    <measurement group_id="O3" value="50.5" lower_limit="37.0" upper_limit="64.1"/>
                    <measurement group_id="O4" value="73.6" lower_limit="61.8" upper_limit="82.8"/>
                    <measurement group_id="O5" value="67.1" lower_limit="54.0" upper_limit="78.1"/>
                    <measurement group_id="O6" value="84.8" lower_limit="76.4" upper_limit="90.6"/>
                    <measurement group_id="O7" value="80.3" lower_limit="70.1" upper_limit="87.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of the Maximal Response of NVA237 Doses on Forced Expiratory Volume in One Second of Area Under the Curve 12-24 Hours Over Days 1, and 14 of Treatment</title>
        <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Percentage of the maximal response of NVA237 on FEV1 Area under the curve (AUC) 12-24 hours was calculated from measurements taken at 11 hours 55 min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on Days 1 and 14.
AUC FEV1 was measured in response to all doses administered (see Outcome Measure #30). All FEV1 responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All FEV1 data are reported as a percentage of the theoretical maximal response.</description>
        <time_frame>11 hours 55 min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on Days 1 and 14</time_frame>
        <population>Full analysis set includes all randomized patients who received at least one dose of study drug and data available for analysis. Only patients with non-missing values were included.</population>
        <group_list>
          <group group_id="O1">
            <title>NVA237 12.5 µg q.d.</title>
            <description>NVA237 12.5 µg once daily</description>
          </group>
          <group group_id="O2">
            <title>NVA237 25.0 µg q.d.</title>
            <description>NVA237 25.0 µg once daily</description>
          </group>
          <group group_id="O3">
            <title>NVA237 12.5 µg b.i.d.</title>
            <description>NVA237 12.5 µg twice daily</description>
          </group>
          <group group_id="O4">
            <title>NVA237 50.0 µg q.d.</title>
            <description>NVA237 50.0 µg once daily</description>
          </group>
          <group group_id="O5">
            <title>NVA237 25.0 µg b.i.d.</title>
            <description>NVA237 25.0 µg twice daily</description>
          </group>
          <group group_id="O6">
            <title>NVA237 100.0 µg q.d.</title>
            <description>NVA237 100.0 µg once daily</description>
          </group>
          <group group_id="O7">
            <title>NVA237 50.0 µg b.i.d.</title>
            <description>NVA237 50.0 µg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of the Maximal Response of NVA237 Doses on Forced Expiratory Volume in One Second of Area Under the Curve 12-24 Hours Over Days 1, and 14 of Treatment</title>
          <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Percentage of the maximal response of NVA237 on FEV1 Area under the curve (AUC) 12-24 hours was calculated from measurements taken at 11 hours 55 min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on Days 1 and 14.
AUC FEV1 was measured in response to all doses administered (see Outcome Measure #30). All FEV1 responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All FEV1 data are reported as a percentage of the theoretical maximal response.</description>
          <population>Full analysis set includes all randomized patients who received at least one dose of study drug and data available for analysis. Only patients with non-missing values were included.</population>
          <units>Percentage of maximal response* hours</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="94"/>
                <count group_id="O3" value="93"/>
                <count group_id="O4" value="92"/>
                <count group_id="O5" value="96"/>
                <count group_id="O6" value="96"/>
                <count group_id="O7" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (n=89, 94, 93, 92, 96, 96, 87)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.9" lower_limit="1.2" upper_limit="90.7"/>
                    <measurement group_id="O2" value="37.9" lower_limit="2.4" upper_limit="95.2"/>
                    <measurement group_id="O3" value="54.4" lower_limit="4.5" upper_limit="97.8"/>
                    <measurement group_id="O4" value="54.1" lower_limit="4.7" upper_limit="97.6"/>
                    <measurement group_id="O5" value="69.5" lower_limit="8.6" upper_limit="98.9"/>
                    <measurement group_id="O6" value="69.3" lower_limit="9.0" upper_limit="98.8"/>
                    <measurement group_id="O7" value="81.1" lower_limit="15.5" upper_limit="99.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 (n= 86, 92, 91, 91, 95, 93, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.6" lower_limit="15.5" upper_limit="42.5"/>
                    <measurement group_id="O2" value="40.1" lower_limit="24.2" upper_limit="59.6"/>
                    <measurement group_id="O3" value="56.6" lower_limit="31.3" upper_limit="78.2"/>
                    <measurement group_id="O4" value="56.4" lower_limit="32.9" upper_limit="74.7"/>
                    <measurement group_id="O5" value="71.4" lower_limit="41.4" upper_limit="87.8"/>
                    <measurement group_id="O6" value="71.2" lower_limit="42.5" upper_limit="85.5"/>
                    <measurement group_id="O7" value="82.4" lower_limit="51.2" upper_limit="93.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of the Maximal Response of NVA237 Doses on Forced Expiratory Volume in One Second at 12 Hours on Days 1 and 14 of Treatment</title>
        <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Percentage of the maximal response of NVA237 doses on FEV1 at 12 hours was measured on days 1 and 14.
FEV1 was measured in response to all doses administered (see Outcome Measure #31). All FEV1 responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All FEV1 data are reported as a percentage of the theoretical maximal response.</description>
        <time_frame>Days 1 and 14</time_frame>
        <population>Full analysis set includes all randomized patients who received at least one dose of study drug and data available for analysis. Only patients with non-missing values were included.</population>
        <group_list>
          <group group_id="O1">
            <title>NVA237 12.5 µg q.d.</title>
            <description>NVA237 12.5 µg once daily</description>
          </group>
          <group group_id="O2">
            <title>NVA237 25.0 µg q.d.</title>
            <description>NVA237 25.0 µg once daily</description>
          </group>
          <group group_id="O3">
            <title>NVA237 12.5 µg b.i.d.</title>
            <description>NVA237 12.5 µg twice daily</description>
          </group>
          <group group_id="O4">
            <title>NVA237 50.0 µg q.d.</title>
            <description>NVA237 50.0 µg once daily</description>
          </group>
          <group group_id="O5">
            <title>NVA237 25.0 µg b.i.d.</title>
            <description>NVA237 25.0 µg twice daily</description>
          </group>
          <group group_id="O6">
            <title>NVA237 100.0 µg q.d.</title>
            <description>NVA237 100.0 µg once daily</description>
          </group>
          <group group_id="O7">
            <title>NVA237 50.0 µg b.i.d.</title>
            <description>NVA237 50.0 µg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of the Maximal Response of NVA237 Doses on Forced Expiratory Volume in One Second at 12 Hours on Days 1 and 14 of Treatment</title>
          <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Percentage of the maximal response of NVA237 doses on FEV1 at 12 hours was measured on days 1 and 14.
FEV1 was measured in response to all doses administered (see Outcome Measure #31). All FEV1 responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All FEV1 data are reported as a percentage of the theoretical maximal response.</description>
          <population>Full analysis set includes all randomized patients who received at least one dose of study drug and data available for analysis. Only patients with non-missing values were included.</population>
          <units>Percentage of maximal response</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="91"/>
                <count group_id="O3" value="91"/>
                <count group_id="O4" value="90"/>
                <count group_id="O5" value="90"/>
                <count group_id="O6" value="92"/>
                <count group_id="O7" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (n=83, 90, 91, 85, 89, 90, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.1" lower_limit="19.1" upper_limit="55.7"/>
                    <measurement group_id="O2" value="52.0" lower_limit="32.0" upper_limit="71.6"/>
                    <measurement group_id="O3" value="44.4" lower_limit="25.7" upper_limit="64.7"/>
                    <measurement group_id="O4" value="68.4" lower_limit="48.5" upper_limit="83.4"/>
                    <measurement group_id="O5" value="61.5" lower_limit="41.0" upper_limit="78.5"/>
                    <measurement group_id="O6" value="81.2" lower_limit="65.3" upper_limit="91.0"/>
                    <measurement group_id="O7" value="76.1" lower_limit="58.1" upper_limit="88.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 (n=84, 91, 88, 90, 90, 92, 78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.1" lower_limit="14.7" upper_limit="44.6"/>
                    <measurement group_id="O2" value="42.7" lower_limit="25.7" upper_limit="61.7"/>
                    <measurement group_id="O3" value="35.5" lower_limit="20.4" upper_limit="54.0"/>
                    <measurement group_id="O4" value="59.8" lower_limit="40.9" upper_limit="76.3"/>
                    <measurement group_id="O5" value="52.4" lower_limit="33.9" upper_limit="70.2"/>
                    <measurement group_id="O6" value="74.9" lower_limit="58.0" upper_limit="86.6"/>
                    <measurement group_id="O7" value="66.7" lower_limit="50.7" upper_limit="82.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of the Maximal Response of NVA237 Doses on Peak Forced Expiratory Volume in One Second on Days 1, 7 and 14 of Treatment</title>
        <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Peak FEV1 is the maximum FEV1 recorded in a pre-determined period of time.
Percentage of the maximal response of NVA237 doses on Peak FEV1 was measured on days 1, 7 and 14 of treatment.
Peak FEV1 was measured in response to all doses administered (see Outcome Measure #32). All FEV1 responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All FEV1 data are reported as a percentage of the theoretical maximal response.</description>
        <time_frame>Days 1, 7, and 14</time_frame>
        <population>Full analysis set includes all randomized patients who received at least one dose of study drug and data available for analysis. Only patients with non-missing values were included.</population>
        <group_list>
          <group group_id="O1">
            <title>NVA237 12.5 µg q.d.</title>
            <description>NVA237 12.5 µg once daily</description>
          </group>
          <group group_id="O2">
            <title>NVA237 25.0 µg q.d.</title>
            <description>NVA237 25.0 µg once daily</description>
          </group>
          <group group_id="O3">
            <title>NVA237 12.5 µg b.i.d.</title>
            <description>NVA237 12.5 µg twice daily</description>
          </group>
          <group group_id="O4">
            <title>NVA237 50.0 µg q.d.</title>
            <description>NVA237 50.0 µg once daily</description>
          </group>
          <group group_id="O5">
            <title>NVA237 25.0 µg b.i.d.</title>
            <description>NVA237 25.0 µg twice daily</description>
          </group>
          <group group_id="O6">
            <title>NVA237 100.0 µg q.d.</title>
            <description>NVA237 100.0 µg once daily</description>
          </group>
          <group group_id="O7">
            <title>NVA237 50.0 µg b.i.d.</title>
            <description>NVA237 50.0 µg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of the Maximal Response of NVA237 Doses on Peak Forced Expiratory Volume in One Second on Days 1, 7 and 14 of Treatment</title>
          <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Peak FEV1 is the maximum FEV1 recorded in a pre-determined period of time.
Percentage of the maximal response of NVA237 doses on Peak FEV1 was measured on days 1, 7 and 14 of treatment.
Peak FEV1 was measured in response to all doses administered (see Outcome Measure #32). All FEV1 responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All FEV1 data are reported as a percentage of the theoretical maximal response.</description>
          <population>Full analysis set includes all randomized patients who received at least one dose of study drug and data available for analysis. Only patients with non-missing values were included.</population>
          <units>Percentage of maximal response</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="94"/>
                <count group_id="O3" value="93"/>
                <count group_id="O4" value="92"/>
                <count group_id="O5" value="96"/>
                <count group_id="O6" value="96"/>
                <count group_id="O7" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (n=89, 94, 93, 91, 96, 96, 86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.7" lower_limit="47.4" upper_limit="74.7"/>
                    <measurement group_id="O2" value="76.0" lower_limit="62.5" upper_limit="85.5"/>
                    <measurement group_id="O3" value="68.9" lower_limit="54.1" upper_limit="81.1"/>
                    <measurement group_id="O4" value="86.1" lower_limit="75.8" upper_limit="92.2"/>
                    <measurement group_id="O5" value="81.3" lower_limit="68.7" upper_limit="89.6"/>
                    <measurement group_id="O6" value="92.3" lower_limit="85.6" upper_limit="96.0"/>
                    <measurement group_id="O7" value="89.5" lower_limit="80.6" upper_limit="94.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 (n=87, 93, 90, 92, 95, 94, 85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.3" lower_limit="41.2" upper_limit="65.5"/>
                    <measurement group_id="O2" value="69.2" lower_limit="56.7" upper_limit="79.2"/>
                    <measurement group_id="O3" value="61.1" lower_limit="48.2" upper_limit="73.4"/>
                    <measurement group_id="O4" value="81.5" lower_limit="71.1" upper_limit="88.4"/>
                    <measurement group_id="O5" value="75.6" lower_limit="63.4" upper_limit="84.7"/>
                    <measurement group_id="O6" value="89.6" lower_limit="82.4" upper_limit="93.9"/>
                    <measurement group_id="O7" value="85.8" lower_limit="76.5" upper_limit="91.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 (n=86, 92, 91, 91, 95, 93, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.3" lower_limit="41.2" upper_limit="65.5"/>
                    <measurement group_id="O2" value="69.2" lower_limit="56.7" upper_limit="79.2"/>
                    <measurement group_id="O3" value="61.1" lower_limit="48.2" upper_limit="73.4"/>
                    <measurement group_id="O4" value="81.5" lower_limit="71.1" upper_limit="88.4"/>
                    <measurement group_id="O5" value="75.6" lower_limit="63.4" upper_limit="84.7"/>
                    <measurement group_id="O6" value="89.6" lower_limit="82.4" upper_limit="93.9"/>
                    <measurement group_id="O7" value="85.8" lower_limit="76.5" upper_limit="91.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of the Maximal Response of NVA237 Doses on Trough Forced Vital Capacity on Days 1, 7 and 14</title>
        <description>Percentage of the maximal response of NVA237 Doses on Trough Forced Vital Capacity (FVC) on Days 1, 7 and 14. FVC is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Trough FVC was assessed via spirometry. (see Outcome Measure #33).
Trough FVC is defined as the mean of the FVC values measured at 23 hours 15 mins and 23 hours 45 mins post-dose.</description>
        <time_frame>Days 1, 7 and 14</time_frame>
        <population>Full analysis set includes all randomized patients who received at least one dose of study drug and data available for analysis. Only patients with non-missing values were included.</population>
        <group_list>
          <group group_id="O1">
            <title>NVA237 12.5 µg q.d.</title>
            <description>NVA237 12.5 µg once daily</description>
          </group>
          <group group_id="O2">
            <title>NVA237 25.0 µg q.d.</title>
            <description>NVA237 25.0 µg once daily</description>
          </group>
          <group group_id="O3">
            <title>NVA237 12.5 µg b.i.d.</title>
            <description>NVA237 12.5 µg twice daily</description>
          </group>
          <group group_id="O4">
            <title>NVA237 50.0 µg q.d.</title>
            <description>NVA237 50.0 µg once daily</description>
          </group>
          <group group_id="O5">
            <title>NVA237 25.0 µg b.i.d.</title>
            <description>NVA237 25.0 µg twice daily</description>
          </group>
          <group group_id="O6">
            <title>NVA237 100.0 µg q.d.</title>
            <description>NVA237 100.0 µg once daily</description>
          </group>
          <group group_id="O7">
            <title>NVA237 50.0 µg b.i.d.</title>
            <description>NVA237 50.0 µg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of the Maximal Response of NVA237 Doses on Trough Forced Vital Capacity on Days 1, 7 and 14</title>
          <description>Percentage of the maximal response of NVA237 Doses on Trough Forced Vital Capacity (FVC) on Days 1, 7 and 14. FVC is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Trough FVC was assessed via spirometry. (see Outcome Measure #33).
Trough FVC is defined as the mean of the FVC values measured at 23 hours 15 mins and 23 hours 45 mins post-dose.</description>
          <population>Full analysis set includes all randomized patients who received at least one dose of study drug and data available for analysis. Only patients with non-missing values were included.</population>
          <units>Percentage of maximal response</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="92"/>
                <count group_id="O3" value="91"/>
                <count group_id="O4" value="91"/>
                <count group_id="O5" value="95"/>
                <count group_id="O6" value="94"/>
                <count group_id="O7" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (n=88, 92, 91, 90, 94, 94, 87)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.8" lower_limit="11.3" upper_limit="43.5"/>
                    <measurement group_id="O2" value="36.8" lower_limit="19.6" upper_limit="60.9"/>
                    <measurement group_id="O3" value="52.9" lower_limit="26.2" upper_limit="79.9"/>
                    <measurement group_id="O4" value="53.4" lower_limit="30.7" upper_limit="75.8"/>
                    <measurement group_id="O5" value="68.7" lower_limit="38.3" upper_limit="88.9"/>
                    <measurement group_id="O6" value="69.1" lower_limit="43.4" upper_limit="86.3"/>
                    <measurement group_id="O7" value="81.0" lower_limit="52.3" upper_limit="94.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 (n=87, 92, 90, 91, 95, 93, 85, 87)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.3" lower_limit="11.2" upper_limit="45.2"/>
                    <measurement group_id="O2" value="37.4" lower_limit="19.6" upper_limit="62.5"/>
                    <measurement group_id="O3" value="53.6" lower_limit="26.3" upper_limit="81.2"/>
                    <measurement group_id="O4" value="54.0" lower_limit="30.7" upper_limit="77.1"/>
                    <measurement group_id="O5" value="69.3" lower_limit="38.3" upper_limit="89.7"/>
                    <measurement group_id="O6" value="69.7" lower_limit="43.3" upper_limit="87.1"/>
                    <measurement group_id="O7" value="81.4" lower_limit="52.0" upper_limit="94.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 (n= 85, 90, 91, 88, 94, 93, 81, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.3" lower_limit="11.3" upper_limit="45.3"/>
                    <measurement group_id="O2" value="37.4" lower_limit="19.7" upper_limit="65.5"/>
                    <measurement group_id="O3" value="53.6" lower_limit="26.4" upper_limit="81.2"/>
                    <measurement group_id="O4" value="54.0" lower_limit="30.8" upper_limit="77.1"/>
                    <measurement group_id="O5" value="69.3" lower_limit="38.5" upper_limit="89.7"/>
                    <measurement group_id="O6" value="69.7" lower_limit="43.5" upper_limit="87.2"/>
                    <measurement group_id="O7" value="81.4" lower_limit="52.2" upper_limit="94.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Daily Use of Rescue Medication by Treatment at Different Time Points</title>
        <description>Mean daily use of rescue medication by treatment and time points. Baseline was defined as the average of the total number of puffs of rescue medication during the week prior to treatment start, divided by the total number of days with non-missing rescue data during that week, then puffs were counted during weeks 1, 2, 3 and 4 postdose.</description>
        <time_frame>Baseline, Weeks 1, 2, 3 and 4</time_frame>
        <population>Only patients with a non-missing value at both period baseline and the respective post-baseline visit were included. The modeling approach is not suitable for these data as the modeling assumptions do not hold.</population>
        <group_list>
          <group group_id="O1">
            <title>NVA237 12.5 µg q.d.</title>
            <description>NVA237 12.5 µg once daily</description>
          </group>
          <group group_id="O2">
            <title>NVA237 25.0 µg q.d.</title>
            <description>NVA237 25.0 µg once daily</description>
          </group>
          <group group_id="O3">
            <title>NVA237 12.5 µg b.i.d.</title>
            <description>NVA237 12.5 µg twice daily</description>
          </group>
          <group group_id="O4">
            <title>NVA237 50.0 µg q.d.</title>
            <description>NVA237 50.0 µg once daily</description>
          </group>
          <group group_id="O5">
            <title>NVA237 25.0 µg b.i.d.</title>
            <description>NVA237 25.0 µg twice daily</description>
          </group>
          <group group_id="O6">
            <title>NVA237 100.0 µg q.d.</title>
            <description>NVA237 100.0 µg once daily</description>
          </group>
          <group group_id="O7">
            <title>NVA237 50.0 µg b.i.d.</title>
            <description>NVA237 50.0 µg twice daily</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Placebo to NVA237 once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Daily Use of Rescue Medication by Treatment at Different Time Points</title>
          <description>Mean daily use of rescue medication by treatment and time points. Baseline was defined as the average of the total number of puffs of rescue medication during the week prior to treatment start, divided by the total number of days with non-missing rescue data during that week, then puffs were counted during weeks 1, 2, 3 and 4 postdose.</description>
          <population>Only patients with a non-missing value at both period baseline and the respective post-baseline visit were included. The modeling approach is not suitable for these data as the modeling assumptions do not hold.</population>
          <units>Number of Puffs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="95"/>
                <count group_id="O3" value="95"/>
                <count group_id="O4" value="92"/>
                <count group_id="O5" value="96"/>
                <count group_id="O6" value="96"/>
                <count group_id="O7" value="86"/>
                <count group_id="O8" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=89, 95, 95, 92, 96, 96, 86, 91)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.16" spread="3.131"/>
                    <measurement group_id="O2" value="4.16" spread="2.925"/>
                    <measurement group_id="O3" value="3.83" spread="3.218"/>
                    <measurement group_id="O4" value="4.45" spread="3.068"/>
                    <measurement group_id="O5" value="3.47" spread="2.996"/>
                    <measurement group_id="O6" value="4.81" spread="3.276"/>
                    <measurement group_id="O7" value="4.25" spread="3.613"/>
                    <measurement group_id="O8" value="4.62" spread="3.710"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1 (n=89, 95, 95, 91, 96, 96, 86, 90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.41" spread="2.338"/>
                    <measurement group_id="O2" value="2.23" spread="2.158"/>
                    <measurement group_id="O3" value="2.10" spread="2.337"/>
                    <measurement group_id="O4" value="2.36" spread="2.291"/>
                    <measurement group_id="O5" value="2.13" spread="2.349"/>
                    <measurement group_id="O6" value="2.53" spread="2.609"/>
                    <measurement group_id="O7" value="2.54" spread="2.678"/>
                    <measurement group_id="O8" value="2.94" spread="3.075"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n=86, 94, 94, 91, 95, 93, 84, 89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.74" spread="2.784"/>
                    <measurement group_id="O2" value="2.20" spread="2.054"/>
                    <measurement group_id="O3" value="2.22" spread="2.541"/>
                    <measurement group_id="O4" value="2.38" spread="2.541"/>
                    <measurement group_id="O5" value="2.08" spread="2.568"/>
                    <measurement group_id="O6" value="2.59" spread="2.658"/>
                    <measurement group_id="O7" value="2.82" spread="3.003"/>
                    <measurement group_id="O8" value="3.32" spread="3.455"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 (n= 86, 93, 94, 89, 93, 93, 83, 87)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.75" spread="2.736"/>
                    <measurement group_id="O2" value="2.40" spread="2.316"/>
                    <measurement group_id="O3" value="2.29" spread="2.354"/>
                    <measurement group_id="O4" value="2.37" spread="2.580"/>
                    <measurement group_id="O5" value="2.23" spread="2.743"/>
                    <measurement group_id="O6" value="2.75" spread="2.868"/>
                    <measurement group_id="O7" value="2.69" spread="2.977"/>
                    <measurement group_id="O8" value="3.34" spread="3.660"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=86, 92, 94, 88, 93, 93, 82, 85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.91" spread="2.968"/>
                    <measurement group_id="O2" value="2.52" spread="2.476"/>
                    <measurement group_id="O3" value="2.42" spread="2.773"/>
                    <measurement group_id="O4" value="2.46" spread="2.504"/>
                    <measurement group_id="O5" value="2.32" spread="2.990"/>
                    <measurement group_id="O6" value="2.65" spread="2.828"/>
                    <measurement group_id="O7" value="2.78" spread="2.899"/>
                    <measurement group_id="O8" value="3.41" spread="3.761"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximal Response of Incremental Once Daily and Twice Daily Doses of NVA237 That Each Dose Achieves in Relation to the Maximal Effect of NVA237 on Trough Forced Expiratory Volume in One Second at Day 28</title>
        <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. The maximal response of incremental once daily and twice daily doses of NVA237 that each dose achieves in relation to the maximal effect of NVA237 on Trough FEV1 was measured at Day 28. FEV1 was measured in response to all doses administered (see Outcome Measure #19).
All trough FEV1 responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All trough FEV1 data are reported as a percentage of the theoretical maximal response.
Trough FEV1 was defined as the mean of the 23 hour 15 minute and 23 hour 45 minute post-dose values.</description>
        <time_frame>Day 28</time_frame>
        <population>Full analysis set includes all randomized patients who received at least one dose of study drug and data available for analysis. Only patients with non-missing values were included.</population>
        <group_list>
          <group group_id="O1">
            <title>NVA237 12.5 µg q.d.</title>
            <description>NVA237 12.5 µg once daily</description>
          </group>
          <group group_id="O2">
            <title>NVA237 25.0 µg q.d.</title>
            <description>NVA237 25.0 µg once daily</description>
          </group>
          <group group_id="O3">
            <title>NVA237 12.5 µg b.i.d.</title>
            <description>NVA237 12.5 µg twice daily</description>
          </group>
          <group group_id="O4">
            <title>NVA237 50.0 µg q.d.</title>
            <description>NVA237 50.0 µg once daily</description>
          </group>
          <group group_id="O5">
            <title>NVA237 25.0 µg b.i.d.</title>
            <description>NVA237 25.0 µg twice daily</description>
          </group>
          <group group_id="O6">
            <title>NVA237 100.0 µg q.d.</title>
            <description>NVA237 100.0 µg once daily</description>
          </group>
          <group group_id="O7">
            <title>NVA237 50.0 µg b.i.d.</title>
            <description>NVA237 50.0 µg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Maximal Response of Incremental Once Daily and Twice Daily Doses of NVA237 That Each Dose Achieves in Relation to the Maximal Effect of NVA237 on Trough Forced Expiratory Volume in One Second at Day 28</title>
          <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. The maximal response of incremental once daily and twice daily doses of NVA237 that each dose achieves in relation to the maximal effect of NVA237 on Trough FEV1 was measured at Day 28. FEV1 was measured in response to all doses administered (see Outcome Measure #19).
All trough FEV1 responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All trough FEV1 data are reported as a percentage of the theoretical maximal response.
Trough FEV1 was defined as the mean of the 23 hour 15 minute and 23 hour 45 minute post-dose values.</description>
          <population>Full analysis set includes all randomized patients who received at least one dose of study drug and data available for analysis. Only patients with non-missing values were included.</population>
          <units>Percentage of maximal response</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="90"/>
                <count group_id="O4" value="88"/>
                <count group_id="O5" value="87"/>
                <count group_id="O6" value="90"/>
                <count group_id="O7" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.1" spread="0.454" lower_limit="16.4" upper_limit="44.3"/>
                    <measurement group_id="O2" value="42.0" spread="0.471" lower_limit="26.5" upper_limit="61.4"/>
                    <measurement group_id="O3" value="61.6" spread="0.456" lower_limit="36.6" upper_limit="82.1"/>
                    <measurement group_id="O4" value="58.5" spread="0.389" lower_limit="37.5" upper_limit="76.2"/>
                    <measurement group_id="O5" value="75.5" spread="0.508" lower_limit="48.7" upper_limit="90.2"/>
                    <measurement group_id="O6" value="73.0" spread="0.512" lower_limit="49.0" upper_limit="86.5"/>
                    <measurement group_id="O7" value="85.4" spread="0.463" lower_limit="60.4" upper_limit="94.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Trough Forced Expiratory Volume in One Second by Treatment at Day 28</title>
        <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Spirometry was performed according to internationally accepted standards.
Trough FEV1 was defined as the mean of the 23 hour 15 minute and 23 hour 45 minute post-dose values.</description>
        <time_frame>Day 28</time_frame>
        <population>Full analysis set includes all randomized patients who received at least one dose of study drug and data available for analysis. Only patients with non-missing values were included.</population>
        <group_list>
          <group group_id="O1">
            <title>NVA237 12.5 ug q.d.</title>
            <description>NVA237 25 ug once daily</description>
          </group>
          <group group_id="O2">
            <title>NVA237 25 ug q.d.</title>
            <description>NVA237 12.5 ug once daily</description>
          </group>
          <group group_id="O3">
            <title>NVA237 12.5 ug b.i.d.</title>
            <description>NVA237 12.5 ug twice daily</description>
          </group>
          <group group_id="O4">
            <title>NVA237 50 ug q.d.</title>
            <description>NVA237 50 ug once daily</description>
          </group>
          <group group_id="O5">
            <title>NVA237 25 ug b.i.d.</title>
            <description>NVA237 25 ug twice daily</description>
          </group>
          <group group_id="O6">
            <title>NVA237 100 ug q.d.</title>
            <description>NVA237 100 ug once daily</description>
          </group>
          <group group_id="O7">
            <title>NVA237 50 ug b.i.d.</title>
            <description>NVA237 50 ug twice daily</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Placebo to NVA237 once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Forced Expiratory Volume in One Second by Treatment at Day 28</title>
          <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Spirometry was performed according to internationally accepted standards.
Trough FEV1 was defined as the mean of the 23 hour 15 minute and 23 hour 45 minute post-dose values.</description>
          <population>Full analysis set includes all randomized patients who received at least one dose of study drug and data available for analysis. Only patients with non-missing values were included.</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="90"/>
                <count group_id="O4" value="88"/>
                <count group_id="O5" value="87"/>
                <count group_id="O6" value="90"/>
                <count group_id="O7" value="81"/>
                <count group_id="O8" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.319" spread="0.505"/>
                    <measurement group_id="O2" value="1.368" spread="0.436"/>
                    <measurement group_id="O3" value="1.354" spread="0.484"/>
                    <measurement group_id="O4" value="1.340" spread="0.400"/>
                    <measurement group_id="O5" value="1.384" spread="0.472"/>
                    <measurement group_id="O6" value="1.410" spread="0.522"/>
                    <measurement group_id="O7" value="1.493" spread="0.449"/>
                    <measurement group_id="O8" value="1.268" spread="0.483"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Forced Expiratory Volume in One Second Area Under the Curve 0-24 Hours at Day 28 of Treatment</title>
        <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Spirometry was performed according to internationally accepted standards.
FEV1 Area Under the Curve (AUC) measurements were taken at 5 min, 15 min, 1,2,3,4,6,8,10 hours, 11 hours 55 min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on day 28. FEV1 AUC was calculated as the sum of trapezoids divided by the length of time.</description>
        <time_frame>5 min, 15 min, 1,2,3,4,6,8,10 hours, 11 hours 55 min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on day 28</time_frame>
        <population>Full analysis set includes all randomized patients who received at least one dose of study drug and data available for analysis. Only patients with non-missing values were included.</population>
        <group_list>
          <group group_id="O1">
            <title>NVA237 12.5 µg q.d.</title>
            <description>NVA237 12.5 µg once daily</description>
          </group>
          <group group_id="O2">
            <title>NVA237 25.0 µg q.d.</title>
            <description>NVA237 25.0 µg once daily</description>
          </group>
          <group group_id="O3">
            <title>NVA237 12.5 µg b.i.d.</title>
            <description>NVA237 12.5 µg twice daily</description>
          </group>
          <group group_id="O4">
            <title>NVA237 50.0 µg q.d.</title>
            <description>NVA237 50.0 µg once daily</description>
          </group>
          <group group_id="O5">
            <title>NVA237 25.0 µg b.i.d.</title>
            <description>NVA237 25.0 µg twice daily</description>
          </group>
          <group group_id="O6">
            <title>NVA237 100.0 µg q.d.</title>
            <description>NVA237 100.0 µg once daily</description>
          </group>
          <group group_id="O7">
            <title>NVA237 50.0 µg b.i.d.</title>
            <description>NVA237 50.0 µg twice daily</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Placebo to NVA237 once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in One Second Area Under the Curve 0-24 Hours at Day 28 of Treatment</title>
          <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Spirometry was performed according to internationally accepted standards.
FEV1 Area Under the Curve (AUC) measurements were taken at 5 min, 15 min, 1,2,3,4,6,8,10 hours, 11 hours 55 min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on day 28. FEV1 AUC was calculated as the sum of trapezoids divided by the length of time.</description>
          <population>Full analysis set includes all randomized patients who received at least one dose of study drug and data available for analysis. Only patients with non-missing values were included.</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="91"/>
                <count group_id="O4" value="90"/>
                <count group_id="O5" value="92"/>
                <count group_id="O6" value="91"/>
                <count group_id="O7" value="82"/>
                <count group_id="O8" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.307" spread="0.469"/>
                    <measurement group_id="O2" value="1.351" spread="0.392"/>
                    <measurement group_id="O3" value="1.321" spread="0.469"/>
                    <measurement group_id="O4" value="1.317" spread="0.390"/>
                    <measurement group_id="O5" value="1.339" spread="0.462"/>
                    <measurement group_id="O6" value="1.395" spread="0.496"/>
                    <measurement group_id="O7" value="1.457" spread="0.453"/>
                    <measurement group_id="O8" value="1.247" spread="0.467"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Forced Expiratory Volume in One Second Area Under the Curve at Different Time Points (0-4 Hours, 0-8 Hours, 0-12 Hours, 12-24 Hours)</title>
        <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Spirometry was performed according to internationally accepted standards.
FEV1 Area Under the Curve (AUC) measurements were taken at: 5 min,15 min, 1,2,3,4,6,8,10 hours, 11 hours 55 min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose). FEV1 AUC was calculated as the sum of trapezoids divided by the length of time.</description>
        <time_frame>5 min,15 min, 1,2,3,4,6,8,10 hours, 11 hours 55 min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on day 28</time_frame>
        <population>Full analysis set includes all randomized patients who received at least one dose of study drug and data available for analysis. Only patients with non-missing values were included.</population>
        <group_list>
          <group group_id="O1">
            <title>NVA237 12.5 µg q.d.</title>
            <description>NVA237 12.5 µg once daily</description>
          </group>
          <group group_id="O2">
            <title>NVA237 25.0 µg q.d.</title>
            <description>NVA237 25.0 µg once daily</description>
          </group>
          <group group_id="O3">
            <title>NVA237 12.5 µg b.i.d.</title>
            <description>NVA237 12.5 µg twice daily</description>
          </group>
          <group group_id="O4">
            <title>NVA237 50.0 µg q.d.</title>
            <description>NVA237 50.0 µg once daily</description>
          </group>
          <group group_id="O5">
            <title>NVA237 25.0 µg b.i.d.</title>
            <description>NVA237 25.0 µg twice daily</description>
          </group>
          <group group_id="O6">
            <title>NVA237 100.0 µg q.d.</title>
            <description>NVA237 100.0 µg once daily</description>
          </group>
          <group group_id="O7">
            <title>NVA237 50.0 µg b.i.d.</title>
            <description>NVA237 50.0 µg twice daily</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Placebo to NVA237 once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in One Second Area Under the Curve at Different Time Points (0-4 Hours, 0-8 Hours, 0-12 Hours, 12-24 Hours)</title>
          <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Spirometry was performed according to internationally accepted standards.
FEV1 Area Under the Curve (AUC) measurements were taken at: 5 min,15 min, 1,2,3,4,6,8,10 hours, 11 hours 55 min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose). FEV1 AUC was calculated as the sum of trapezoids divided by the length of time.</description>
          <population>Full analysis set includes all randomized patients who received at least one dose of study drug and data available for analysis. Only patients with non-missing values were included.</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="91"/>
                <count group_id="O4" value="90"/>
                <count group_id="O5" value="92"/>
                <count group_id="O6" value="91"/>
                <count group_id="O7" value="82"/>
                <count group_id="O8" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC 0-4h (n=82,90,91,89,92,91,82,82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.415" spread="0.494"/>
                    <measurement group_id="O2" value="1.478" spread="0.439"/>
                    <measurement group_id="O3" value="1.414" spread="0.489"/>
                    <measurement group_id="O4" value="1.431" spread="0.411"/>
                    <measurement group_id="O5" value="1.417" spread="0.487"/>
                    <measurement group_id="O6" value="1.490" spread="0.532"/>
                    <measurement group_id="O7" value="1.553" spread="0.504"/>
                    <measurement group_id="O8" value="1.315" spread="0.490"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC 0-8h (n=82,90,91,90,92,91,82,82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.386" spread="0.477"/>
                    <measurement group_id="O2" value="1.447" spread="0.423"/>
                    <measurement group_id="O3" value="1.392" spread="0.491"/>
                    <measurement group_id="O4" value="1.397" spread="0.411"/>
                    <measurement group_id="O5" value="1.397" spread="0.476"/>
                    <measurement group_id="O6" value="1.461" spread="0.520"/>
                    <measurement group_id="O7" value="1.527" spread="0.495"/>
                    <measurement group_id="O8" value="1.305" spread="0.485"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC 0-12h (n=82,90,91,90,92,91,82,82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.364" spread="0.480"/>
                    <measurement group_id="O2" value="1.416" spread="0.416"/>
                    <measurement group_id="O3" value="1.362" spread="0.487"/>
                    <measurement group_id="O4" value="1.377" spread="0.408"/>
                    <measurement group_id="O5" value="1.375" spread="0.469"/>
                    <measurement group_id="O6" value="1.442" spread="0.515"/>
                    <measurement group_id="O7" value="1.505" spread="0.480"/>
                    <measurement group_id="O8" value="1.285" spread="0.476"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC 12-24h (n=82,90,91,89,92,91,81,82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.251" spread="0.464"/>
                    <measurement group_id="O2" value="1.287" spread="0.382"/>
                    <measurement group_id="O3" value="1.280" spread="0.458"/>
                    <measurement group_id="O4" value="1.264" spread="0.378"/>
                    <measurement group_id="O5" value="1.299" spread="0.459"/>
                    <measurement group_id="O6" value="1.350" spread="0.480"/>
                    <measurement group_id="O7" value="1.421" spread="0.426"/>
                    <measurement group_id="O8" value="1.208" spread="0.461"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Forced Expiratory Volume in One Second at 12 Hours on Day 28 of Treatment</title>
        <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Spirometry was performed according to internationally accepted standards.</description>
        <time_frame>12 hours on day 28</time_frame>
        <population>Full analysis set includes all randomized patients who received at least one dose of study drug and data available for analysis. Only patients with non-missing values were included.</population>
        <group_list>
          <group group_id="O1">
            <title>NVA237 12.5 µg q.d.</title>
            <description>NVA237 12.5 µg once daily</description>
          </group>
          <group group_id="O2">
            <title>NVA237 25.0 µg q.d.</title>
            <description>NVA237 25.0 µg once daily</description>
          </group>
          <group group_id="O3">
            <title>NVA237 12.5 µg b.i.d.</title>
            <description>NVA237 12.5 µg twice daily</description>
          </group>
          <group group_id="O4">
            <title>NVA237 50.0 µg q.d.</title>
            <description>NVA237 50.0 µg once daily</description>
          </group>
          <group group_id="O5">
            <title>NVA237 25.0 µg b.i.d.</title>
            <description>NVA237 25.0 µg twice daily</description>
          </group>
          <group group_id="O6">
            <title>NVA237 100.0 µg q.d.</title>
            <description>NVA237 100.0 µg once daily</description>
          </group>
          <group group_id="O7">
            <title>NVA237 50.0 µg b.i.d.</title>
            <description>NVA237 50.0 µg twice daily</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Placebo to NVA237 once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in One Second at 12 Hours on Day 28 of Treatment</title>
          <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Spirometry was performed according to internationally accepted standards.</description>
          <population>Full analysis set includes all randomized patients who received at least one dose of study drug and data available for analysis. Only patients with non-missing values were included.</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="91"/>
                <count group_id="O4" value="85"/>
                <count group_id="O5" value="87"/>
                <count group_id="O6" value="88"/>
                <count group_id="O7" value="78"/>
                <count group_id="O8" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.272" spread="0.471"/>
                    <measurement group_id="O2" value="1.330" spread="0.415"/>
                    <measurement group_id="O3" value="1.279" spread="0.476"/>
                    <measurement group_id="O4" value="1.330" spread="0.384"/>
                    <measurement group_id="O5" value="1.320" spread="0.466"/>
                    <measurement group_id="O6" value="1.391" spread="0.498"/>
                    <measurement group_id="O7" value="1.429" spread="0.449"/>
                    <measurement group_id="O8" value="1.256" spread="0.472"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Peak Forced Expiratory Volume in One Second at Day 28 of Treatment</title>
        <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Spirometry was performed according to internationally accepted standards.
Peak FEV1 is the maximum FEV1 recorded in a pre-determined period of time. Measurements were taken at 25 min , 15 min pre-dose, 5 min, 15 min, 1 , 2 ,3 , 4 , 6 , 8 , 10 hours , 11 hour 55 min and 14 hour post-dose on day 28.</description>
        <time_frame>25 min , 15 min pre-dose, 5 min, 15 min, 1 , 2 ,3 , 4 , 6 , 8 , 10 hours , 11 hour 55 min and 14 hour post-dose on day 28</time_frame>
        <population>Full analysis set includes all randomized patients who received at least one dose of study drug and data available for analysis. Only patients with non-missing values were included.</population>
        <group_list>
          <group group_id="O1">
            <title>NVA237 12.5 µg q.d.</title>
            <description>NVA237 12.5 µg once daily</description>
          </group>
          <group group_id="O2">
            <title>NVA237 25.0 µg q.d.</title>
            <description>NVA237 25.0 µg once daily</description>
          </group>
          <group group_id="O3">
            <title>NVA237 12.5 µg b.i.d.</title>
            <description>NVA237 12.5 µg twice daily</description>
          </group>
          <group group_id="O4">
            <title>NVA237 50.0 µg q.d.</title>
            <description>NVA237 50.0 µg once daily</description>
          </group>
          <group group_id="O5">
            <title>NVA237 25.0 µg b.i.d.</title>
            <description>NVA237 25.0 µg twice daily</description>
          </group>
          <group group_id="O6">
            <title>NVA237 100.0 µg q.d.</title>
            <description>NVA237 100.0 µg once daily</description>
          </group>
          <group group_id="O7">
            <title>NVA237 50.0 µg b.i.d.</title>
            <description>NVA237 50.0 µg twice daily</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Placebo to NVA237 once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Forced Expiratory Volume in One Second at Day 28 of Treatment</title>
          <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Spirometry was performed according to internationally accepted standards.
Peak FEV1 is the maximum FEV1 recorded in a pre-determined period of time. Measurements were taken at 25 min , 15 min pre-dose, 5 min, 15 min, 1 , 2 ,3 , 4 , 6 , 8 , 10 hours , 11 hour 55 min and 14 hour post-dose on day 28.</description>
          <population>Full analysis set includes all randomized patients who received at least one dose of study drug and data available for analysis. Only patients with non-missing values were included.</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="91"/>
                <count group_id="O4" value="89"/>
                <count group_id="O5" value="92"/>
                <count group_id="O6" value="91"/>
                <count group_id="O7" value="82"/>
                <count group_id="O8" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.500" spread="0.516"/>
                    <measurement group_id="O2" value="1.563" spread="0.453"/>
                    <measurement group_id="O3" value="1.494" spread="0.507"/>
                    <measurement group_id="O4" value="1.514" spread="0.432"/>
                    <measurement group_id="O5" value="1.504" spread="0.516"/>
                    <measurement group_id="O6" value="1.570" spread="0.546"/>
                    <measurement group_id="O7" value="1.630" spread="0.513"/>
                    <measurement group_id="O8" value="1.397" spread="0.515"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Trough Forced Vital Capacity After 28 Days of Treatment</title>
        <description>Forced Vital Capacity (FVC) after 28 days of treatment. FVC is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. FVC was assessed via spirometry. Trough FVC was defined as the mean of the FVC values measured at 23 hours 15 mins and 23 hours 45 mins post-dose.</description>
        <time_frame>23 hours 15 mins and 23 hours 45 mins post-dose on Day 28</time_frame>
        <population>Full analysis set includes all randomized patients who received at least one dose of study drug and data available for analysis. Only patients with non-missing values were included.</population>
        <group_list>
          <group group_id="O1">
            <title>NVA237 12.5 µg q.d.</title>
            <description>NVA237 12.5 µg once daily</description>
          </group>
          <group group_id="O2">
            <title>NVA237 25.0 µg q.d.</title>
            <description>NVA237 25.0 µg once daily</description>
          </group>
          <group group_id="O3">
            <title>NVA237 12.5 µg b.i.d.</title>
            <description>NVA237 12.5 µg twice daily</description>
          </group>
          <group group_id="O4">
            <title>NVA237 50.0 µg q.d.</title>
            <description>NVA237 50.0 µg once daily</description>
          </group>
          <group group_id="O5">
            <title>NVA237 25.0 µg b.i.d.</title>
            <description>NVA237 25.0 µg twice daily</description>
          </group>
          <group group_id="O6">
            <title>NVA237 100.0 µg q.d.</title>
            <description>NVA237 100.0 µg once daily</description>
          </group>
          <group group_id="O7">
            <title>NVA237 50.0 µg b.i.d.</title>
            <description>NVA237 50.0 µg twice daily</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Placebo to NVA237 once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Forced Vital Capacity After 28 Days of Treatment</title>
          <description>Forced Vital Capacity (FVC) after 28 days of treatment. FVC is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. FVC was assessed via spirometry. Trough FVC was defined as the mean of the FVC values measured at 23 hours 15 mins and 23 hours 45 mins post-dose.</description>
          <population>Full analysis set includes all randomized patients who received at least one dose of study drug and data available for analysis. Only patients with non-missing values were included.</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="90"/>
                <count group_id="O4" value="88"/>
                <count group_id="O5" value="87"/>
                <count group_id="O6" value="90"/>
                <count group_id="O7" value="81"/>
                <count group_id="O8" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.939" spread="0.878"/>
                    <measurement group_id="O2" value="3.007" spread="0.910"/>
                    <measurement group_id="O3" value="2.954" spread="0.849"/>
                    <measurement group_id="O4" value="2.973" spread="0.825"/>
                    <measurement group_id="O5" value="3.041" spread="0.770"/>
                    <measurement group_id="O6" value="2.974" spread="0.999"/>
                    <measurement group_id="O7" value="3.080" spread="0.913"/>
                    <measurement group_id="O8" value="2.703" spread="0.857"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Trough Forced Expiratory Volume in One Second at Days 1, 7 and 14</title>
        <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Spirometry was performed according to internationally accepted standards.
Trough FEV1 was measured on Days 1, 7 and 14 of treatment. Trough FEV1 was defined as the mean of the FEV1 values measured at 23 hours 15 mins and 23 hours 45 mins post-dose.</description>
        <time_frame>23 hours 15 mins and 23 hours 45 mins post-dose on Days 1, 7 and 14</time_frame>
        <population>Full analysis set includes all randomized patients who received at least one dose of study drug and data available for analysis. Only patients with non-missing values were included.</population>
        <group_list>
          <group group_id="O1">
            <title>NVA237 12.5 µg q.d.</title>
            <description>NVA237 12.5 µg once daily</description>
          </group>
          <group group_id="O2">
            <title>NVA237 25.0 µg q.d.</title>
            <description>NVA237 25.0 µg once daily</description>
          </group>
          <group group_id="O3">
            <title>NVA237 12.5 µg b.i.d.</title>
            <description>NVA237 12.5 µg twice daily</description>
          </group>
          <group group_id="O4">
            <title>NVA237 50.0 µg q.d.</title>
            <description>NVA237 50.0 µg once daily</description>
          </group>
          <group group_id="O5">
            <title>NVA237 25.0 µg b.i.d.</title>
            <description>NVA237 25.0 µg twice daily</description>
          </group>
          <group group_id="O6">
            <title>NVA237 100.0 µg q.d.</title>
            <description>NVA237 100.0 µg once daily</description>
          </group>
          <group group_id="O7">
            <title>NVA237 50.0 µg b.i.d.</title>
            <description>NVA237 50.0 µg twice daily</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Placebo to NVA237 once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Forced Expiratory Volume in One Second at Days 1, 7 and 14</title>
          <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Spirometry was performed according to internationally accepted standards.
Trough FEV1 was measured on Days 1, 7 and 14 of treatment. Trough FEV1 was defined as the mean of the FEV1 values measured at 23 hours 15 mins and 23 hours 45 mins post-dose.</description>
          <population>Full analysis set includes all randomized patients who received at least one dose of study drug and data available for analysis. Only patients with non-missing values were included.</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="92"/>
                <count group_id="O3" value="91"/>
                <count group_id="O4" value="91"/>
                <count group_id="O5" value="95"/>
                <count group_id="O6" value="94"/>
                <count group_id="O7" value="87"/>
                <count group_id="O8" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (n= 88,92,91, 90, 94, 94, 87, 86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.299" spread="0.490"/>
                    <measurement group_id="O2" value="1.387" spread="0.477"/>
                    <measurement group_id="O3" value="1.375" spread="0.477"/>
                    <measurement group_id="O4" value="1.371" spread="0.406"/>
                    <measurement group_id="O5" value="1.355" spread="0.503"/>
                    <measurement group_id="O6" value="1.367" spread="0.514"/>
                    <measurement group_id="O7" value="1.492" spread="0.483"/>
                    <measurement group_id="O8" value="1.290" spread="0.471"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 (n= 87,92,90, 91, 95, 93, 85, 87)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.332" spread="0.499"/>
                    <measurement group_id="O2" value="1.422" spread="0.432"/>
                    <measurement group_id="O3" value="1.349" spread="0.467"/>
                    <measurement group_id="O4" value="1.391" spread="0.392"/>
                    <measurement group_id="O5" value="1.375" spread="0.486"/>
                    <measurement group_id="O6" value="1.372" spread="0.501"/>
                    <measurement group_id="O7" value="1.480" spread="0.474"/>
                    <measurement group_id="O8" value="1.294" spread="0.491"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 (n= 85,90,91, 88, 94, 93, 81, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.336" spread="0.442"/>
                    <measurement group_id="O2" value="1.349" spread="0.446"/>
                    <measurement group_id="O3" value="1.335" spread="0.444"/>
                    <measurement group_id="O4" value="1.356" spread="0.391"/>
                    <measurement group_id="O5" value="1.359" spread="0.479"/>
                    <measurement group_id="O6" value="1.375" spread="0.519"/>
                    <measurement group_id="O7" value="1.500" spread="0.455"/>
                    <measurement group_id="O8" value="1.284" spread="0.471"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Forced Expiratory Volume in One Second Area Under the Curve 0-24 Hours on Days 1 and 14 of Treatment</title>
        <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Spirometry was performed according to internationally accepted standards.
FEV1 Area Under the Curve (AUC) measurements were taken at 5 min, 15 min, 1,2,3,4,6,8,10 hours, 11 hours 55 min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on days 1 and 14 of treatment. FEV1 AUC was calculated as the sum of trapezoids divided by the length of time.</description>
        <time_frame>5 min, 15 min, 1,2,3,4,6,8,10 hours, 11 hours 55 min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on days 1 and 14</time_frame>
        <population>Full analysis set includes all randomized patients who received at least one dose of study drug and data available for analysis. Only patients with non-missing values were included.</population>
        <group_list>
          <group group_id="O1">
            <title>NVA237 12.5 µg q.d.</title>
            <description>NVA237 12.5 µg once daily</description>
          </group>
          <group group_id="O2">
            <title>NVA237 25.0 µg q.d.</title>
            <description>NVA237 25.0 µg once daily</description>
          </group>
          <group group_id="O3">
            <title>NVA237 12.5 µg b.i.d.</title>
            <description>NVA237 12.5 µg twice daily</description>
          </group>
          <group group_id="O4">
            <title>NVA237 50.0 µg q.d.</title>
            <description>NVA237 50.0 µg once daily</description>
          </group>
          <group group_id="O5">
            <title>NVA237 25.0 µg b.i.d.</title>
            <description>NVA237 25.0 µg twice daily</description>
          </group>
          <group group_id="O6">
            <title>NVA237 100.0 µg q.d.</title>
            <description>NVA237 100.0 µg once daily</description>
          </group>
          <group group_id="O7">
            <title>NVA237 50.0 µg b.i.d.</title>
            <description>NVA237 50.0 µg twice daily</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Placebo to NVA237 once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in One Second Area Under the Curve 0-24 Hours on Days 1 and 14 of Treatment</title>
          <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Spirometry was performed according to internationally accepted standards.
FEV1 Area Under the Curve (AUC) measurements were taken at 5 min, 15 min, 1,2,3,4,6,8,10 hours, 11 hours 55 min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on days 1 and 14 of treatment. FEV1 AUC was calculated as the sum of trapezoids divided by the length of time.</description>
          <population>Full analysis set includes all randomized patients who received at least one dose of study drug and data available for analysis. Only patients with non-missing values were included.</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="94"/>
                <count group_id="O3" value="93"/>
                <count group_id="O4" value="92"/>
                <count group_id="O5" value="96"/>
                <count group_id="O6" value="96"/>
                <count group_id="O7" value="87"/>
                <count group_id="O8" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (n= 89,94,93,92,96,96,87,90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.318" spread="0.470"/>
                    <measurement group_id="O2" value="1.370" spread="0.444"/>
                    <measurement group_id="O3" value="1.354" spread="0.462"/>
                    <measurement group_id="O4" value="1.361" spread="0.393"/>
                    <measurement group_id="O5" value="1.336" spread="0.460"/>
                    <measurement group_id="O6" value="1.376" spread="0.526"/>
                    <measurement group_id="O7" value="1.466" spread="0.471"/>
                    <measurement group_id="O8" value="1.256" spread="0.469"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 (n= 86,92,91,91,95,93,84,86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.306" spread="0.427"/>
                    <measurement group_id="O2" value="1.353" spread="0.420"/>
                    <measurement group_id="O3" value="1.324" spread="0.430"/>
                    <measurement group_id="O4" value="1.348" spread="0.372"/>
                    <measurement group_id="O5" value="1.335" spread="0.460"/>
                    <measurement group_id="O6" value="1.386" spread="0.493"/>
                    <measurement group_id="O7" value="1.449" spread="0.453"/>
                    <measurement group_id="O8" value="1.253" spread="0.473"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Forced Expiratory Volume in One Second Area Under the Curve 0-4 Hours on Days 1, 7 and 14 of Treatment</title>
        <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Spirometry was performed according to internationally accepted standards.
FEV1 Area Under the Curve (AUC) measurements were taken at 5 min, 15 min, 1,2,3,4 hours (postdose) on days 1, 7 and 14 of treatment. FEV1 AUC was calculated as the sum of trapezoids divided by the length of time.</description>
        <time_frame>5 min,15 min, 1,2,3,4 hours (postdose) on Days 1, 7 and 14</time_frame>
        <population>Full analysis set includes all randomized patients who received at least one dose of study drug and data available for analysis. Only patients with non-missing values were included.</population>
        <group_list>
          <group group_id="O1">
            <title>NVA237 12.5 µg q.d.</title>
            <description>NVA237 12.5 µg once daily</description>
          </group>
          <group group_id="O2">
            <title>NVA237 25.0 µg q.d.</title>
            <description>NVA237 25.0 µg once daily</description>
          </group>
          <group group_id="O3">
            <title>NVA237 12.5 µg b.i.d.</title>
            <description>NVA237 12.5 µg twice daily</description>
          </group>
          <group group_id="O4">
            <title>NVA237 50.0 µg q.d.</title>
            <description>NVA237 50.0 µg once daily</description>
          </group>
          <group group_id="O5">
            <title>NVA237 25.0 µg b.i.d.</title>
            <description>NVA237 25.0 µg twice daily</description>
          </group>
          <group group_id="O6">
            <title>NVA237 100.0 µg q.d.</title>
            <description>NVA237 100.0 µg once daily</description>
          </group>
          <group group_id="O7">
            <title>NVA237 50.0 µg b.i.d.</title>
            <description>NVA237 50.0 µg twice daily</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Placebo to NVA237 once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in One Second Area Under the Curve 0-4 Hours on Days 1, 7 and 14 of Treatment</title>
          <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Spirometry was performed according to internationally accepted standards.
FEV1 Area Under the Curve (AUC) measurements were taken at 5 min, 15 min, 1,2,3,4 hours (postdose) on days 1, 7 and 14 of treatment. FEV1 AUC was calculated as the sum of trapezoids divided by the length of time.</description>
          <population>Full analysis set includes all randomized patients who received at least one dose of study drug and data available for analysis. Only patients with non-missing values were included.</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="94"/>
                <count group_id="O3" value="93"/>
                <count group_id="O4" value="92"/>
                <count group_id="O5" value="96"/>
                <count group_id="O6" value="96"/>
                <count group_id="O7" value="86"/>
                <count group_id="O8" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (n=89,94,93,91,96,96,86,89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.428" spread="0.492"/>
                    <measurement group_id="O2" value="1.483" spread="0.485"/>
                    <measurement group_id="O3" value="1.421" spread="0.489"/>
                    <measurement group_id="O4" value="1.469" spread="0.428"/>
                    <measurement group_id="O5" value="1.411" spread="0.483"/>
                    <measurement group_id="O6" value="1.453" spread="0.551"/>
                    <measurement group_id="O7" value="1.533" spread="0.501"/>
                    <measurement group_id="O8" value="1.312" spread="0.494"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 (n=87,93,90,92,95,94,85,89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.403" spread="0.468"/>
                    <measurement group_id="O2" value="1.483" spread="0.463"/>
                    <measurement group_id="O3" value="1.397" spread="0.478"/>
                    <measurement group_id="O4" value="1.432" spread="0.407"/>
                    <measurement group_id="O5" value="1.390" spread="0.472"/>
                    <measurement group_id="O6" value="1.453" spread="0.505"/>
                    <measurement group_id="O7" value="1.537" spread="0.494"/>
                    <measurement group_id="O8" value="1.310" spread="0.491"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 (n=86,92,91,91,95,93,84,86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.451" spread="0.456"/>
                    <measurement group_id="O2" value="1.473" spread="0.456"/>
                    <measurement group_id="O3" value="1.390" spread="0.471"/>
                    <measurement group_id="O4" value="1.468" spread="0.409"/>
                    <measurement group_id="O5" value="1.429" spread="0.503"/>
                    <measurement group_id="O6" value="1.460" spread="0.514"/>
                    <measurement group_id="O7" value="1.545" spread="0.485"/>
                    <measurement group_id="O8" value="1.314" spread="0.500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Forced Expiratory Volume in One Second of Area Under the Curve 0-8 Hours Days 1, 7, and 14</title>
        <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Percentage of the maximal response of NVA237 doses on FEV1 Area Under the Curve (AUC) 0-8 was calculated from measurements taken at 5 min,15 min, 1,2,3,4,6,8 hours (postdose) on days 1, 7, and 14. FEV1 AUC was calculated as the sum of trapezoids divided by the length of time.</description>
        <time_frame>at 5 min,15 min, 1,2,3,4,6,8 hours (postdose) on days 1, 7 and 14</time_frame>
        <population>Full analysis set includes all randomized patients who received at least one dose of study drug and data available for analysis. Only patients with non-missing values were included.</population>
        <group_list>
          <group group_id="O1">
            <title>NVA237 12.5 µg q.d.</title>
            <description>NVA237 12.5 µg once daily</description>
          </group>
          <group group_id="O2">
            <title>NVA237 25.0 µg q.d.</title>
            <description>NVA237 25.0 µg once daily</description>
          </group>
          <group group_id="O3">
            <title>NVA237 12.5 µg b.i.d.</title>
            <description>NVA237 12.5 µg twice daily</description>
          </group>
          <group group_id="O4">
            <title>NVA237 50.0 µg q.d.</title>
            <description>NVA237 50.0 µg once daily</description>
          </group>
          <group group_id="O5">
            <title>NVA237 25.0 µg b.i.d.</title>
            <description>NVA237 25.0 µg twice daily</description>
          </group>
          <group group_id="O6">
            <title>NVA237 100.0 µg q.d.</title>
            <description>NVA237 100.0 µg once daily</description>
          </group>
          <group group_id="O7">
            <title>NVA237 50.0 µg b.i.d.</title>
            <description>NVA237 50.0 µg twice daily</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Placebo to NVA237 once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in One Second of Area Under the Curve 0-8 Hours Days 1, 7, and 14</title>
          <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Percentage of the maximal response of NVA237 doses on FEV1 Area Under the Curve (AUC) 0-8 was calculated from measurements taken at 5 min,15 min, 1,2,3,4,6,8 hours (postdose) on days 1, 7, and 14. FEV1 AUC was calculated as the sum of trapezoids divided by the length of time.</description>
          <population>Full analysis set includes all randomized patients who received at least one dose of study drug and data available for analysis. Only patients with non-missing values were included.</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="94"/>
                <count group_id="O3" value="93"/>
                <count group_id="O4" value="92"/>
                <count group_id="O5" value="96"/>
                <count group_id="O6" value="96"/>
                <count group_id="O7" value="87"/>
                <count group_id="O8" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (n=89, 94, 93, 91, 96, 96, 87, 90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.400" spread="0.486"/>
                    <measurement group_id="O2" value="1.450" spread="0.476"/>
                    <measurement group_id="O3" value="1.401" spread="0.483"/>
                    <measurement group_id="O4" value="1.451" spread="0.426"/>
                    <measurement group_id="O5" value="1.390" spread="0.476"/>
                    <measurement group_id="O6" value="1.446" spread="0.548"/>
                    <measurement group_id="O7" value="1.519" spread="0.493"/>
                    <measurement group_id="O8" value="1.301" spread="0.488"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 (n= 87, 93, 91, 92, 95, 94, 85, 89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.386" spread="0.471"/>
                    <measurement group_id="O2" value="1.462" spread="0.455"/>
                    <measurement group_id="O3" value="1.375" spread="0.464"/>
                    <measurement group_id="O4" value="1.409" spread="0.397"/>
                    <measurement group_id="O5" value="1.373" spread="0.470"/>
                    <measurement group_id="O6" value="1.433" spread="0.503"/>
                    <measurement group_id="O7" value="1.516" spread="0.481"/>
                    <measurement group_id="O8" value="1.293" spread="0.489"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 (n=86, 92, 91, 91, 95, 93, 84, 86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.381" spread="0.453"/>
                    <measurement group_id="O2" value="1.441" spread="0.452"/>
                    <measurement group_id="O3" value="1.375" spread="0.463"/>
                    <measurement group_id="O4" value="1.435" spread="0.398"/>
                    <measurement group_id="O5" value="1.400" spread="0.486"/>
                    <measurement group_id="O6" value="1.442" spread="0.508"/>
                    <measurement group_id="O7" value="1.514" spread="0.479"/>
                    <measurement group_id="O8" value="1.293" spread="0.498"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Forced Expiratory Volume in One Second Area Under the Curve 0-12 Hours at Day 1 and 14 of Treatment</title>
        <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Percentage of the maximal response of NVA237 doses was calculated on FEV1 Area Under the Curve (AUC) 0-12 hours from measurements taken at at 5 min,15 min, 1,2,3,4,6,8,10 hours, 11h 55 min (postdose) on days 1 and 14. FEV1 AUC was calculated as the sum of trapezoids divided by the length of time.</description>
        <time_frame>5 min,15 min, 1,2,3,4,6,8,10 hours, 11h 55 min (postdose) on days 1 and 14</time_frame>
        <population>Full analysis set includes all randomized patients who received at least one dose of study drug and data available for analysis. Only patients with non-missing values were included.</population>
        <group_list>
          <group group_id="O1">
            <title>NVA237 12.5 µg q.d.</title>
            <description>NVA237 12.5 µg once daily</description>
          </group>
          <group group_id="O2">
            <title>NVA237 25.0 µg q.d.</title>
            <description>NVA237 25.0 µg once daily</description>
          </group>
          <group group_id="O3">
            <title>NVA237 12.5 µg b.i.d.</title>
            <description>NVA237 12.5 µg twice daily</description>
          </group>
          <group group_id="O4">
            <title>NVA237 50.0 µg q.d.</title>
            <description>NVA237 50.0 µg once daily</description>
          </group>
          <group group_id="O5">
            <title>NVA237 25.0 µg b.i.d.</title>
            <description>NVA237 25.0 µg twice daily</description>
          </group>
          <group group_id="O6">
            <title>NVA237 100.0 µg q.d.</title>
            <description>NVA237 100.0 µg once daily</description>
          </group>
          <group group_id="O7">
            <title>NVA237 50.0 µg b.i.d.</title>
            <description>NVA237 50.0 µg twice daily</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Placebo to NVA237 once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in One Second Area Under the Curve 0-12 Hours at Day 1 and 14 of Treatment</title>
          <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Percentage of the maximal response of NVA237 doses was calculated on FEV1 Area Under the Curve (AUC) 0-12 hours from measurements taken at at 5 min,15 min, 1,2,3,4,6,8,10 hours, 11h 55 min (postdose) on days 1 and 14. FEV1 AUC was calculated as the sum of trapezoids divided by the length of time.</description>
          <population>Full analysis set includes all randomized patients who received at least one dose of study drug and data available for analysis. Only patients with non-missing values were included.</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="94"/>
                <count group_id="O3" value="93"/>
                <count group_id="O4" value="91"/>
                <count group_id="O5" value="96"/>
                <count group_id="O6" value="96"/>
                <count group_id="O7" value="87"/>
                <count group_id="O8" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (n=89, 94, 93, 91, 96, 96, 87, 90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.382" spread="0.488"/>
                    <measurement group_id="O2" value="1.425" spread="0.465"/>
                    <measurement group_id="O3" value="1.379" spread="0.474"/>
                    <measurement group_id="O4" value="1.430" spread="0.421"/>
                    <measurement group_id="O5" value="1.364" spread="0.470"/>
                    <measurement group_id="O6" value="1.431" spread="0.544"/>
                    <measurement group_id="O7" value="1.498" spread="0.484"/>
                    <measurement group_id="O8" value="1.289" spread="0.482"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 (n=86, 92, 91, 91, 95, 93, 84, 86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.360" spread="0.447"/>
                    <measurement group_id="O2" value="1.416" spread="0.445"/>
                    <measurement group_id="O3" value="1.357" spread="0.452"/>
                    <measurement group_id="O4" value="1.406" spread="0.388"/>
                    <measurement group_id="O5" value="1.378" spread="0.480"/>
                    <measurement group_id="O6" value="1.427" spread="0.503"/>
                    <measurement group_id="O7" value="1.494" spread="0.472"/>
                    <measurement group_id="O8" value="1.281" spread="0.493"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Forced Expiratory Volume in One Second of Area Under the Curve 12-24 Hours Over Days 1, and 14 of Treatment</title>
        <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Percentage of the maximal response of NVA237 on FEV1 Area under the curve (AUC) 12-24 hours was calculated from measurements taken at 11 hours 55 min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on Days 1 and 14. FEV1 AUC was calculated as the sum of trapezoids divided by the length of time.</description>
        <time_frame>11 hours 55 min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on Days 1 and 14</time_frame>
        <population>Full analysis set includes all randomized patients who received at least one dose of study drug and data available for analysis. Only patients with non-missing values were included.</population>
        <group_list>
          <group group_id="O1">
            <title>NVA237 12.5 µg q.d.</title>
            <description>NVA237 12.5 µg once daily</description>
          </group>
          <group group_id="O2">
            <title>NVA237 25.0 µg q.d.</title>
            <description>NVA237 25.0 µg once daily</description>
          </group>
          <group group_id="O3">
            <title>NVA237 12.5 µg b.i.d.</title>
            <description>NVA237 12.5 µg twice daily</description>
          </group>
          <group group_id="O4">
            <title>NVA237 50.0 µg q.d.</title>
            <description>NVA237 50.0 µg once daily</description>
          </group>
          <group group_id="O5">
            <title>NVA237 25.0 µg b.i.d.</title>
            <description>NVA237 25.0 µg twice daily</description>
          </group>
          <group group_id="O6">
            <title>NVA237 100.0 µg q.d.</title>
            <description>NVA237 100.0 µg once daily</description>
          </group>
          <group group_id="O7">
            <title>NVA237 50.0 µg b.i.d.</title>
            <description>NVA237 50.0 µg twice daily</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Placebo to NVA237 once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in One Second of Area Under the Curve 12-24 Hours Over Days 1, and 14 of Treatment</title>
          <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Percentage of the maximal response of NVA237 on FEV1 Area under the curve (AUC) 12-24 hours was calculated from measurements taken at 11 hours 55 min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on Days 1 and 14. FEV1 AUC was calculated as the sum of trapezoids divided by the length of time.</description>
          <population>Full analysis set includes all randomized patients who received at least one dose of study drug and data available for analysis. Only patients with non-missing values were included.</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="94"/>
                <count group_id="O3" value="93"/>
                <count group_id="O4" value="92"/>
                <count group_id="O5" value="96"/>
                <count group_id="O6" value="96"/>
                <count group_id="O7" value="87"/>
                <count group_id="O8" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (n=89, 94, 93, 92, 96, 96, 87, 90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.257" spread="0.459"/>
                    <measurement group_id="O2" value="1.315" spread="0.432"/>
                    <measurement group_id="O3" value="1.329" spread="0.455"/>
                    <measurement group_id="O4" value="1.295" spread="0.375"/>
                    <measurement group_id="O5" value="1.306" spread="0.454"/>
                    <measurement group_id="O6" value="1.322" spread="0.512"/>
                    <measurement group_id="O7" value="1.437" spread="0.461"/>
                    <measurement group_id="O8" value="1.224" spread="0.459"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 (n= 86, 92, 91, 91, 95, 93, 84, 86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.251" spread="0.417"/>
                    <measurement group_id="O2" value="1.289" spread="0.405"/>
                    <measurement group_id="O3" value="1.290" spread="0.415"/>
                    <measurement group_id="O4" value="1.291" spread="0.366"/>
                    <measurement group_id="O5" value="1.291" spread="0.450"/>
                    <measurement group_id="O6" value="1.344" spread="0.488"/>
                    <measurement group_id="O7" value="1.406" spread="0.437"/>
                    <measurement group_id="O8" value="1.225" spread="0.459"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Forced Expiratory Volume in One Second at 12 Hours on Days 1 and 14 of Treatment</title>
        <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Percentage of the maximal response of NVA237 doses on FEV1 at 12 hours was measured on days 1 and 14.</description>
        <time_frame>Days 1 and 14</time_frame>
        <population>Full analysis set includes all randomized patients who received at least one dose of study drug and data available for analysis. Only patients with non-missing values were included.</population>
        <group_list>
          <group group_id="O1">
            <title>NVA237 12.5 µg q.d.</title>
            <description>NVA237 12.5 µg once daily</description>
          </group>
          <group group_id="O2">
            <title>NVA237 25.0 µg q.d.</title>
            <description>NVA237 25.0 µg once daily</description>
          </group>
          <group group_id="O3">
            <title>NVA237 12.5 µg b.i.d.</title>
            <description>NVA237 12.5 µg twice daily</description>
          </group>
          <group group_id="O4">
            <title>NVA237 50.0 µg q.d.</title>
            <description>NVA237 50.0 µg once daily</description>
          </group>
          <group group_id="O5">
            <title>NVA237 25.0 µg b.i.d.</title>
            <description>NVA237 25.0 µg twice daily</description>
          </group>
          <group group_id="O6">
            <title>NVA237 100.0 µg q.d.</title>
            <description>NVA237 100.0 µg once daily</description>
          </group>
          <group group_id="O7">
            <title>NVA237 50.0 µg b.i.d.</title>
            <description>NVA237 50.0 µg twice daily</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Placebo to NVA237 once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in One Second at 12 Hours on Days 1 and 14 of Treatment</title>
          <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Percentage of the maximal response of NVA237 doses on FEV1 at 12 hours was measured on days 1 and 14.</description>
          <population>Full analysis set includes all randomized patients who received at least one dose of study drug and data available for analysis. Only patients with non-missing values were included.</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="91"/>
                <count group_id="O3" value="91"/>
                <count group_id="O4" value="90"/>
                <count group_id="O5" value="90"/>
                <count group_id="O6" value="92"/>
                <count group_id="O7" value="83"/>
                <count group_id="O8" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (n=83, 90, 91, 85, 89, 90, 83, 81)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.319" spread="0.502"/>
                    <measurement group_id="O2" value="1.364" spread="0.452"/>
                    <measurement group_id="O3" value="1.327" spread="0.465"/>
                    <measurement group_id="O4" value="1.345" spread="0.405"/>
                    <measurement group_id="O5" value="1.299" spread="0.457"/>
                    <measurement group_id="O6" value="1.374" spread="0.549"/>
                    <measurement group_id="O7" value="1.439" spread="0.459"/>
                    <measurement group_id="O8" value="1.244" spread="0.449"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 (n=84, 91, 88, 90, 90, 92, 78, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.290" spread="0.431"/>
                    <measurement group_id="O2" value="1.356" spread="0.431"/>
                    <measurement group_id="O3" value="1.303" spread="0.428"/>
                    <measurement group_id="O4" value="1.329" spread="0.368"/>
                    <measurement group_id="O5" value="1.329" spread="0.455"/>
                    <measurement group_id="O6" value="1.389" spread="0.506"/>
                    <measurement group_id="O7" value="1.469" spread="0.436"/>
                    <measurement group_id="O8" value="1.268" spread="0.477"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Peak Forced Expiratory Volume in One Second on Days 1, 7 and 14 of Treatment</title>
        <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Peak FEV1 is the maximum FEV1 recorded in a pre-determined period of time.
Percentage of the maximal response of NVA237 doses on Peak FEV1 was measured on days 1, 7 and 14 of treatment.</description>
        <time_frame>Days 1, 7, and 14</time_frame>
        <population>Full analysis set includes all randomized patients who received at least one dose of study drug and data available for analysis. Only patients with non-missing values were included.</population>
        <group_list>
          <group group_id="O1">
            <title>NVA237 12.5 µg q.d.</title>
            <description>NVA237 12.5 µg once daily</description>
          </group>
          <group group_id="O2">
            <title>NVA237 25.0 µg q.d.</title>
            <description>NVA237 25.0 µg once daily</description>
          </group>
          <group group_id="O3">
            <title>NVA237 12.5 µg b.i.d.</title>
            <description>NVA237 12.5 µg twice daily</description>
          </group>
          <group group_id="O4">
            <title>NVA237 50.0 µg q.d.</title>
            <description>NVA237 50.0 µg once daily</description>
          </group>
          <group group_id="O5">
            <title>NVA237 25.0 µg b.i.d.</title>
            <description>NVA237 25.0 µg twice daily</description>
          </group>
          <group group_id="O6">
            <title>NVA237 100.0 µg q.d.</title>
            <description>NVA237 100.0 µg once daily</description>
          </group>
          <group group_id="O7">
            <title>NVA237 50.0 µg b.i.d.</title>
            <description>NVA237 50.0 µg twice daily</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Placebo to NVA237 once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Forced Expiratory Volume in One Second on Days 1, 7 and 14 of Treatment</title>
          <description>Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Peak FEV1 is the maximum FEV1 recorded in a pre-determined period of time.
Percentage of the maximal response of NVA237 doses on Peak FEV1 was measured on days 1, 7 and 14 of treatment.</description>
          <population>Full analysis set includes all randomized patients who received at least one dose of study drug and data available for analysis. Only patients with non-missing values were included.</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="94"/>
                <count group_id="O3" value="93"/>
                <count group_id="O4" value="92"/>
                <count group_id="O5" value="96"/>
                <count group_id="O6" value="96"/>
                <count group_id="O7" value="86"/>
                <count group_id="O8" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (n=89, 94, 93, 91, 96, 96, 86, 89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.503" spread="0.515"/>
                    <measurement group_id="O2" value="1.558" spread="0.497"/>
                    <measurement group_id="O3" value="1.494" spread="0.507"/>
                    <measurement group_id="O4" value="1.541" spread="0.442"/>
                    <measurement group_id="O5" value="1.483" spread="0.495"/>
                    <measurement group_id="O6" value="1.521" spread="0.567"/>
                    <measurement group_id="O7" value="1.597" spread="0.510"/>
                    <measurement group_id="O8" value="1.378" spread="0.504"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 (n=87, 93, 90, 92, 95, 94, 85, 89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.459" spread="0.477"/>
                    <measurement group_id="O2" value="1.540" spread="0.474"/>
                    <measurement group_id="O3" value="1.455" spread="0.496"/>
                    <measurement group_id="O4" value="1.501" spread="0.426"/>
                    <measurement group_id="O5" value="1.448" spread="0.491"/>
                    <measurement group_id="O6" value="1.513" spread="0.524"/>
                    <measurement group_id="O7" value="1.598" spread="0.510"/>
                    <measurement group_id="O8" value="1.364" spread="0.504"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 (n=86, 92, 91, 91, 95, 93, 84, 86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.487" spread="0.471"/>
                    <measurement group_id="O2" value="1.547" spread="0.465"/>
                    <measurement group_id="O3" value="1.465" spread="0.484"/>
                    <measurement group_id="O4" value="1.537" spread="0.429"/>
                    <measurement group_id="O5" value="1.506" spread="0.513"/>
                    <measurement group_id="O6" value="1.528" spread="0.529"/>
                    <measurement group_id="O7" value="1.615" spread="0.497"/>
                    <measurement group_id="O8" value="1.380" spread="0.509"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Trough Forced Vital Capacity on Days 1, 7 and 14</title>
        <description>Trough Forced Vital Capacity (FVC) on Days 1, 7 and 14. FVC is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. FVC was assessed via spirometry. (see Outcome Measure #23).
Trough FVC was defined as the mean of the 23 hour 15 minute and 23 hour 45 minute post-dose values.</description>
        <time_frame>Days 1, 7 and 14</time_frame>
        <population>Full analysis set includes all randomized patients who received at least one dose of study drug and data available for analysis. Only patients with non-missing values were included.</population>
        <group_list>
          <group group_id="O1">
            <title>NVA237 12.5 µg q.d.</title>
            <description>NVA237 12.5 µg once daily</description>
          </group>
          <group group_id="O2">
            <title>NVA237 25.0 µg q.d.</title>
            <description>NVA237 25.0 µg once daily</description>
          </group>
          <group group_id="O3">
            <title>NVA237 12.5 µg b.i.d.</title>
            <description>NVA237 12.5 µg twice daily</description>
          </group>
          <group group_id="O4">
            <title>NVA237 50.0 µg q.d.</title>
            <description>NVA237 50.0 µg once daily</description>
          </group>
          <group group_id="O5">
            <title>NVA237 25.0 µg b.i.d.</title>
            <description>NVA237 25.0 µg twice daily</description>
          </group>
          <group group_id="O6">
            <title>NVA237 100.0 µg q.d.</title>
            <description>NVA237 100.0 µg once daily</description>
          </group>
          <group group_id="O7">
            <title>NVA237 50.0 µg b.i.d.</title>
            <description>NVA237 50.0 µg twice daily</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Placebo to NVA237 once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Forced Vital Capacity on Days 1, 7 and 14</title>
          <description>Trough Forced Vital Capacity (FVC) on Days 1, 7 and 14. FVC is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. FVC was assessed via spirometry. (see Outcome Measure #23).
Trough FVC was defined as the mean of the 23 hour 15 minute and 23 hour 45 minute post-dose values.</description>
          <population>Full analysis set includes all randomized patients who received at least one dose of study drug and data available for analysis. Only patients with non-missing values were included.</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="92"/>
                <count group_id="O3" value="91"/>
                <count group_id="O4" value="91"/>
                <count group_id="O5" value="95"/>
                <count group_id="O6" value="94"/>
                <count group_id="O7" value="87"/>
                <count group_id="O8" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (n=88, 92, 91, 90, 94, 94, 87, 86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.895" spread="0.830"/>
                    <measurement group_id="O2" value="3.063" spread="0.967"/>
                    <measurement group_id="O3" value="2.997" spread="0.835"/>
                    <measurement group_id="O4" value="3.017" spread="0.820"/>
                    <measurement group_id="O5" value="2.956" spread="0.810"/>
                    <measurement group_id="O6" value="2.944" spread="1.001"/>
                    <measurement group_id="O7" value="3.088" spread="0.961"/>
                    <measurement group_id="O8" value="2.779" spread="0.838"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 (n=87, 92, 90, 91, 95, 93, 85, 87)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.982" spread="0.833"/>
                    <measurement group_id="O2" value="3.135" spread="0.928"/>
                    <measurement group_id="O3" value="2.991" spread="0.873"/>
                    <measurement group_id="O4" value="3.072" spread="0.833"/>
                    <measurement group_id="O5" value="2.993" spread="0.798"/>
                    <measurement group_id="O6" value="2.977" spread="0.987"/>
                    <measurement group_id="O7" value="3.114" spread="0.975"/>
                    <measurement group_id="O8" value="2.759" spread="0.875"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 (n= 85, 90, 91, 88, 94, 93, 81, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.958" spread="0.772"/>
                    <measurement group_id="O2" value="3.000" spread="0.934"/>
                    <measurement group_id="O3" value="2.965" spread="0.862"/>
                    <measurement group_id="O4" value="3.003" spread="0.812"/>
                    <measurement group_id="O5" value="2.960" spread="0.763"/>
                    <measurement group_id="O6" value="2.941" spread="0.987"/>
                    <measurement group_id="O7" value="3.113" spread="0.941"/>
                    <measurement group_id="O8" value="2.744" spread="0.841"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>NVA237 12.5 ug q.d.</title>
          <description>NVA237 12.5 ug q.d.</description>
        </group>
        <group group_id="E2">
          <title>NVA237 25 ug q.d.</title>
          <description>NVA237 25 ug q.d.</description>
        </group>
        <group group_id="E3">
          <title>NVA237 12.5 ug b.i.d.</title>
          <description>NVA237 12.5 ug b.i.d.</description>
        </group>
        <group group_id="E4">
          <title>NVA237 50 ug q.d.</title>
          <description>NVA237 50 ug q.d.</description>
        </group>
        <group group_id="E5">
          <title>NVA237 25 ug b.i.d.</title>
          <description>NVA237 25 ug b.i.d.</description>
        </group>
        <group group_id="E6">
          <title>NVA237 100 ug q.d.</title>
          <description>NVA237 100 ug q.d.</description>
        </group>
        <group group_id="E7">
          <title>NVA237 50 ug b.i.d.</title>
          <description>NVA237 50 ug b.i.d.</description>
        </group>
        <group group_id="E8">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="96"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="96"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="96"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="96"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="87"/>
                <counts group_id="E8" subjects_affected="14" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="96"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="96"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="87"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="96"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="96"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="87"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="96"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>41 61 324 1111</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

